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Abstract 
Vitronectin is a multifunctional glycoprotein found in both the circulation and the 
extracellular matrix (ECM). Through its capacity to interact with a wide variety of ligands it 
helps to mediate several key physiological processes. These include coagulation, cell adhesion 
and migration, tumor metastasis and tissue remodeling, and immune system response. An 
interesting feature of the protein is its ability to adopt different functional forms, presumably as a 
result ofvarying physiological conditions. A monomeric form ofvitronectin found in the 
circulation helps to regulate proteolytic cascades. Conversely, a multi me ric form ofvitronectin 
found in the ECM helps to regulate pericellular proteolysis as well as cell adhesion and 
migration. The process by which the monomer assembles into higher order complexes remains 
relatively uncharacterized, but is believed to be mediated by the binding ofvitronectin to 
physiological partners including plasminogen activator inhibitor type-l (PAl-I). This results in a 
structural change that is proposed to promote intermolecular self-association via polymerization 
of the central ~-propeller domain. 
The structures of several homologous proteins with a four-bladed ~-propeller motif have 
been solved, but these naturally occurring ~-sheet proteins typically do not associate into higher 
order oligomers. This suggests that in these cases regulatory features must exist which inhibit ~­
sheet interaction in favor of the monomeric protein. An extensive analysis ofknown ~-sheet 
protein structures in the database (Richardson, JS., Richardson, DC. 2002. PNAS. 99:2754-2759) 
has resulted in a set of rules for ~-strands that govern the formation of more extensive intra- or 
intermolecular structures. These authors suggest that certain features of ~-edge strands may be 
responsible for preventing propagation via hydrogen bonding to additional ~-strands. This 
analysis was used as a general guideline to examine the edge residues in the ~-propeller structure 
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for the central domain of vitronectin in order to predict the features responsible for its associative 
behavior. Molecular models of the protein were studied and compared with homologous proteins 
known not to participate in self-association in order to make predictions about specific edge 
strands and amino acid residues involved. These observations were used to test predicted 
polymerization schemes via site directed mutagenesis of specific edge residues. Features noted in 
the Richardson study that prevented ~-sheet interactions were incorporated at key points within 
the central domain ofvitronectin. This strategy should provide valuable insight into the 
mechanistic aspect of the formation of vitronectin complexes. Furthermore, this study serves as 
an important test of the notion that specific structural features may serve as a "negative design" 
to inhibit ~-sheet association and can be used to distinguish central and peripheral strands in ~­
propeller structures. 
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Introduction 
Vitronectin is a human plasma glycoprotein found in both the circulation and the 
extracellular matrix (ECM). Produced primarily in the liver, it has the capacity to interact with a 
wide variety of ligands which helps it to mediate such key physiological processes as 
coagulation, cell adhesion and migration, tumor metastasis and tissue remodeling, and immune 
system response (Xu et al. 2001). Since its discovery in 1967, extensive research has been 
performed with the primary focus of characterizing the binding sites for various ligands. The 
desire to better understand the functionality of the protein, however, necessitates a better 
understanding of its three dimensional structure. Although vitronectin has not been successfully 
crystallized and remains too large for high-resolution structural determination by NMR, a 
general sense of its organization can be surmised from preliminary data. 
Vitronectin is organized into three separate domains that allow for the numerous 
biochemical properties of the functional protein. The 53-residue N-terminal domain consists of 
44 amino acids identical to the circulating 
Domain Structure of Vitronectin 
protein somatomedin B (Suzuki et alI984). 
Contained within this domain are binding 
sites for plasminogen activator inhibitor type 
1 (PAl -1) (Sieffert et al. 1991), integrins 
§, ~ 
Y Y YN C 
1-51 54-130 131-323 3U-456 (Cherney et al. 1993), and the urokinase 
Fig. 1. Domain structure of vitronectin. The Structures for the 
N-terminal somatomedin B, central II-propeller, and C-terminal 
heparin binding domains as predicted by combined plasminogen activator receptor (uPAR) 
computational analyses and NMR measurements. Lynn et al 
(2005) Biochemistry 44, 565-74. (Deng et ale 1996). An unstructured linker 
region (residues 54-130) connects the N-
terminal domain with a central domain (residues 131-342) thought to mediate binding to some 
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bacteria including Staphylococcus aureus and Staphylococcus pyogenes (Liang et al. 1993, 
1997). The C-terminal domain (residues 347-459) serves as the binding site for several ligands 
including heparin (Kost et ale 1992) and collagen (Ishikawa-Sakurai et ale 1993). 
Computational threading and docking algorithms (Xu et al. 2001), while somewhat 
unsuccessful for the N-terminal somatomedin B (SMB) domain, have predicted a four bladed~­
propeller fold for the central domain (probability> 99%) and a two bladed ~-propeller fold for 
the C-terminal domain (probability> 90%). Subsequent studies have solved the structure of the 
5MB domain through two-dimensional NMR (Mayasundari et al. 2004) and peptide mapping to 
identify disulfide bonds (Hom et al. 2004). Additional studies using small angle x-ray scattering 
measurements (Lynn et al. 2004) have successfully generated low resolution models predicting 
an overall peanut shape for the intact protein ( see cover). 
As these models indicate, the central domain of vitronectin contains extensive ~­
sheet content. We hypothesize that this feature makes the central domain integral for one of 
vitronectin's more notable features, its ability to adopt different functional forms presumably as a 
result of varying physiological conditions. A monomeric form of vitronectin is found in the 
circulation where it helps to mediate proteolytic cascades. Conversely, a multinleric form of 
vitronectin is found in the ECM where it helps to regulate pericellular proteolysis, cell adhesion, 
and cell migration. The process by which the monomer assembles into higher order complexes 
remains relatively uncharacterized, but is believed to be mediated by the binding ofvitronectin to 
PAl -1, one of its most physiologically significant binding partners. 
Through its association with vitronectin, PAI-l plays a key role in the remodeling of the 
extracellular matrix that occurs during physiological processes like fibrinolysis and cell 
migration and pathophysiological processes like tumor growth and metastasis (Reuning et al. 
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1998). A serine protease inhibitor (serpin), PAI-l is the primary inhibitor ofboth the urokinase-
and tissue-type plasminogen activators which allows it to regulate vascular and pericellular 
plasmin-mediated proteolysis. Although PAI-l is conformationally labile and has a tendancy to 
spontaneously adopt a more stable yet inactive conformation, its circulating form is found 
primarily in association with vitronectin which has been demonstrated to substantially increase 
its half life (Declereck et ale 1988). 
Both PAI-l and vitronectin have been shown to co-localize to areas of active ECM 
remodeling as occurs with tissue injury or tumor invasion (Bloemendal et al. 2004). While PAI-l 
is secreted locally into the pericellular environment, vitronectin is incorporated from a 
circulatory pool by an undefmed mechanism. Several lines of evidence show that, in addition to 
the stabilization effect vitronectin has on PAl -1, PAl-1 reciprocally affects the binding properties 
of vitro nee tin. Namely, the binding 
Proposed Vitronectin Oligomerization Scheme 
ofPAI-l to vitronectin has been 
show to convert the protein to a 
multimeric form that displays 
enhanced binding to the ECM 
(Minor et al. 2002). A later 
sedimentation velocity analysis 
ECM (Minor et al. 2005) has provided a 
Fig. 2. The interaction ofvitronectin with PAI-l in a 2:1 mechanism for the assembly of these 
stoichiometry induces a conformational change in the protein (1) 
which favors self association and the formation of multivalent 
vitronectin complexes (2) through intermolecular IJ-sheet complexes in a stepwise and 
polymerization of the central domain. These large complexes are 
highly stable and display enhanced binding to the extracellular concentration-dependent manner. 
matrix. 
Low concentrations ofP AI -1 occupy 
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a single high affinity binding site in the 5MB domain and form a 1:1 soluble complex. Higher 
concentrations ofPAl-1 have been shown to bind to a second lower affinity binding site (Podor 
et al. 2000) on vitronectin forming a 2: 1 insoluble complex with localization and function 
distinctly different from its plasma counterpart (Bloemendal et al. 2004). It was demonstrated 
that PAI-l bound to both vitronectin binding sites simultaneously, and suggested that this 
formation of a 2:1 complex is the critical step for the assembly ofhigher order complexes (Minor 
et al. 2005). Unpublished stopped- flow kinetics data from this lab indicate that the unique 2: 1 
P AI-l/vitronectin complex undergoes a conformational change allowing assembly of the 4: 1 
complex and ultimately large oligomers with altered function. 
On a structural level, we hypothesize that it is the central domain of vitronectin with its 
extensive ~-sheet content that allows the formation of these complexes through intermolecular 
associations of its ~-sheets. It has been well established that ~-propellers are prominent structures 
for the intermolecular associations of proteins. This is supported by protein interactions such as 
the WD-40 structures in signal transduction (Chen et al. 2004), ~-propeller domains in matrix 
metalloproteinases (Stricker et al. 2001), and the head regions of integrins that recognize ECM 
ligands (Springer et al. 2002). These examples are supporting evidence for this idea that the 
central domain is the primary mediator of intermolecular associations. Furthermore, both the N­
terminal and C-terminal domains have been eliminated as candidates for involvement in the 
formation of higher order complexes. The 5MB domain when isolated has been shown to be 
stable and monomeric under physiological conditions (Mayasundari et al. 2004), and the folding 
and denaturation ofvitronectin have shown that binding of the heparin ligand to the C-terminal 
domain does not disrupt the formation of higher-order complexes (Zhuang et al. 1996). 
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The structures of several homologous proteins with a four-bladed propeller motif have 
also been solved, but these naturally occurring ~-sheet proteins typically do not associate into 
higher order oligomers. This suggests that in these cases regulatory features must exist that 
inhibit ~-sheet interaction in favor of the monomeric protein. Additionally, unchecked ~-bonding 
has been implicated in the pathology ofmany diseases such as the fibrillar structure associated 
with some neurodegenerative disorders including Alzheimer's (Kirschner et al. 1986). Extensive 
analysis of~-sheet proteins performed by Richardson et al. (2004) has resulted in a set of rules 
for ~-strands that govern the formation ofmore extensive intra- or intermolecular structures. The 
results of this study showed that ~-sheet proteins use various combinations of ~-bulges, pro lines, 
charged residues, short edge strands, and loop shielding to prevent aggregation and maintain 
solubility. 
Structurally, ~-propeller proteins are known to exist in conformations of four to eight 
radial blades comprised of up-and-down ~-sheet structures. The innermost edges of the structure 
are protected from further ~-interactions by the inherent fold of the molecule. Among the 
different edge blocking strategies used, the Richardson study identified two predominant patterns 
that were observed in approximately thirty of the thirty-five ~-propeller structures in the sample. 
The first strategy is the placement of a charged side chain on a low-curvature surface next to the 
edge strand where it would be buried most by potential ~-sheet associations. The location of this 
chain is variable - it may be on the edge strand itself, on the next strand, or even contributed by 
an adjacent structure. The second predominant strategy is the use of a ~-bulge or proline residue 
to disfavor further ~-sheet interactions via structural hindrance of ~-bonding on the convex side 
of the strand. This study also identified several less common means ofprotection employed by ~­
edge residues with the general observation being that the edge strands ofmost naturally 
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occurring ~-sheet proteins are shielded, irregular, short, or otherwise made unsuitable for further 
interactions. These mechanisms serve to promote stability over aggregation, and are termed 
negative design as they do not improve the general structure of the ~-sheet, but exist as a 
preventative measure for an undesirable alternative. 
Aims of this Research Plan 
One important implication of the Richardson study is that one may use specific structural 
features to distinguish central and peripheral strands in ~-propeller structures, and that these 
features may be incorporated as a means to inhibit intermolecular ~-sheet associations. Our 
hypothesis is that the PAI-I induced formation ofvitronectin complexes is mediated by p-sheet 
associations of the central domain. Based on this, the first goal of this study was to locate and 
characterize the edge residues on the p-propeller region in the central domain of vitronectin. This 
identification was then compared to the negative design features highlighted by the Richardson 
study to make preliminary conjectures about the ability of the edge residues to undergo ~-sheet 
polymerization as a mode of in vivo aggregation resulting in the multimeric matrix form of the 
protein. The ~-propeller structural model was also compared with its homologues that do not 
undergo a self-association event in order to catalogue any differences that may result in disparate 
behavior. After completion of the structural analysis and a general prediction ofedge strand 
involvement in self-association, the second goal was to test these predictions through 
mutagenesis studies. Site directed mutagenesis was used to incorporate negative design features 
in order to further define the edge strands and specific residues involved. This should provide 
valuable insight into the mechanistic aspect of the formation of vitronectin complexes, and help 
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to test the notion that specific structural features may serve as negative design to further inhibit 
~-sheet associations. 
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Materials and Methods 
Structural analysis ofvitronectin and homologues- The proposed ~-propeller structure 
for the central domain of vitronectin (Xu et ale 2001) was compared with the crystal structure of 
its hemopexin (Faber et al. 1995), gelatinase (Gohlke et al. 1996), and collagenase (Gomis-Ruth 
et al. 1996) homologues using the molecular modeling program Insight II. Each of the structures 
was aligned based on common features including the location of bulges and the overall folding 
pattern. Each structure was examined individually to determine which edge strand amino acid 
residues appeared capable ofparticipating in intermolecular ~-sheet bonding. Finally, the edge 
strands identified for each structure were compared in order to identify any sequence homologies 
and obvious negative design strategies incorporated within the structure of the protein. These 
observations were used to design rational mutations for the incorporation of negative design 
within wild-type vitronectin. 
Wild Type: GTRQ PQ 

Mutant: GTRKPQ 
 Oligonucleotide Design-Primers 
Primer: 
GGTACCAGAAAGCCCCAGTT 
were designed with the aid of DNAstar's 
Lasergene 7 genome analysis program. One 
forward primer was created for each 
Wild Type: A VRPGYPKLI 
Mutant: AVRPKYPKLI 
mutation thus allowing for simultaneous 
Primer: 
GCAGTGAGGCCTAAGTACCC 
CAAGC mutagenesis of the same strand of the 
template plasmid. Primer # 1 for the upper 
Fig. 3. This shows the primers constructed for the mutagenesis 
experiments. left strand changed glutamine 331 to a lysine 
residue. It was 20 base pairs in length with a calculated T m of 70°C, one mismatch (asterisked), 
and a sequence of5'-GGTACCAGAA*AGCCCCAGTT-3'. Primer #2 for the lower left strand 
changed glycine 191 to a lysine residue. It was 25 base pairs in length with a calculated Tm of 
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70°C, two mismatches (asterisked), and a sequence of 5'­
GCAGTGAGGCCTA*A*GTACCCCAAGC-3'. Each of these mutations was selected to 
incorporate the charged residue towards the center of the edge strand and have a minimal impact 
on protein folding. 
Mutagenesis/Screening-Site directed mutagenesis was perfonned on wild type 
vitronectin cDNA cloned into the pFastBac expression vector (Gibson et al. 2001) using the 
described primers and the QuikChange Multi Site-Directed Mutagenesis Kit purchased from 
Stratagene. The expression vector was grown in E. coli DH10a cells and prepared with the 
Qiagen plasmid miniprep kit. The experimental reaction was carried out with the following 
mixture: 2.5,.11 lOx QuikChange Multi reaction buffer, 16111 distilled water (to a final volume of 
25IlL), 1111 ds-DNA template (50ng), 2111 primer #1 (lOOng), 1.51l1 primer #2 (lOOng), 1 III dNTP 
mix, and 1 ~Ll QuikChange Multi enzyme blend. The reaction was perfonned for 30 cycles with 
the following temperatures and times: 95°C at 1 minute, 55°C for 1 minute, 65°C for 12 minutes. 
1III of the Dpn I restriction enzyme was added to each amplification reaction to digest any 
remaining template DNA. 1.5III of the Dpn I-treated DNA was transfonned into XL10-Gold 
Ultracompetent Cells which added the second strand to the single stranded mutant plasmid. The 
general transfonnation procedure was as follows: 45111 ofXL10-Gold Ultracompetent cells were 
thawed on ice and mixed with 2111 of ~-mercaptoethanol for 10 minutes. The DNA was then 
added and the mix was incubated on ice for 30 min. The reaction was then heat-pulsed at 42°C 
for 30 seconds after which time 0.5ml ofpreheated (42°C) NZY+ broth was added and the mix 
was incubated with shaking (250 rpm) at 37°C for one hour. The transfonnants were screened by 
plating on LB-ampicillin agar plates. After an incubation period of 16 hours at 37°C, 5 colonies 
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were selected, grown in LB-ampicillin broth, and the DNA was isolated with the Qiagen plasmid 
miniprep kit. Samples were then sequenced to ensure proper incorporation of both mutations. 
Expression in baculovirus-The mutant 
......­ Protein Expression Fig. 4 
protein was expressed using the Bac-to-Bac e~ (ebr)~ ( ~ )
.=. CoIIJipe..... OH1 ..... E. culi c.ls ! ECOIItLocZO tl ~Rec""""aac.N Baculovirus Expression system purchased from 
~i\· --------~----------------------f--------------t=:;::;-
Invitrogen. Recombinant Bacmid DNA was ~~ ':a: ~ ~ @@) @ i ~ « !=:.::. 
000 000000 0 C~·~. obtained by transforming the mutated pFastBac 
IIn«tCfl!th .~ ~~ expression vector into DH10Bac E. coli cells for ~ www.invitrogen.com_.....­
.'YIr"'~ 
transposition into the Bacmid. Successful 
transposition was verified through blue/white selection on LB-agar plates with kanamycin, 
gentamycin, and tetracycline. White colonies were selected and re-streaked on LB-agar plates 
with antibiotics to verify transposition. The recombinant bacmid DNA was then isolated using 
the S.N.A.P. MidiPrep Kit purchased from Invitrogen. 
For the expression in Sf9 insect cells, 9 x 105 Sf9 cells per well were plated in a 6-well 
tissue culture plate in 2 ml ofunsupplemented Grace's Medium and allowed to attach for one 
hour. DNA was transfected into the cells using the Cellfectin reagent purchased from Invitrogen. 
200J.lI of the DNA:lipid complex was added to 0.8ml ofGrace's Medium. This was then added to 
the attached cells which were incubated at 27°C for 5 hours. After the incubation period, the 
DNA:lipid complexes were removed and 2ml of complete growth media were added to the cells 
which were incubated at 27°C for 72 hours. 
After the 72 hour incubation period, the medium containing the PI viral stock was 
collected and centrifuged to remove cells and large debris. This was stored at +4°C protected 
from light. Cell fractions were obtained by boiling the cells in SDS reducing buffer, centrifuging 
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to remove cellular debris, and collecting the lysate. Both the lysate and a sample from the PI 
viral stock were analyzed for protein expression using SDS-P AGE and Western Blot. 
Protein Analysis-Samples from both the cell fraction and the media fraction were 
analyzed for vitronectin content using SDS-P AGE. Samples were initially boiled in SDS­
reducing buffer for five minutes and loaded onto a 10% polyacrylamide gel where they were 
allowed to run at 100V for an hour. After this time span, the gel was subjected to a Western Blot 
and stained with anti-vitronectin antibodies (made in rabbit). The transfer for the Western Blot 
was performed by electroblotting onto nitrocellulose using a Biorad semi-dry blotting system. 
The sponges, nitrocellulose, and gel were saturated with transfer buffer (S7.4g glycine, 12.0g tris 
base, 800ml methanol, 2L water) and blotted at lSV for 30 minutes. After this time, the 
nitrocellulose was soaked in a 10% milk blocking solution at room temperature for 1 hour with 
constant shaking. After the blocking period, it was washed with PBS + 0.1 % weight/volume 
Tween (8g NaCI, 0.2g KCI, 1.44g Na2HP04, 0.24g KH2P04 for PBS and 2g Tween-80, 200mL 
10X PBS for Tween), and placed in blocking solution containing the anti-vitronectin antibodies 
for 1 hour with constant shaking. The filter was again washed with PBSlTween and submerged 
in blocking solution containing goat anti-rabbit antibody conjugated with alkaline phosphate 
horseradish peroxidase for 1 hour at room temperature. After washing again with PBS/Tween, 
the filter was placed in a 4-chloro-1-napthol developing solution and allowed to incubate until 
color appeared. The filters were then washed in tap water to stop the reaction and placed in 
aluminum foil at room temperature to preserve color. 
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Results 
Structural analysis ofvitronectin and homologues-Important information about the 
intermolecular self-association of vitronectin is gained from an analysis of the central domain 
believed to be the primary mediator. A proposed structural model for the central ~-propeller 
domain (Xu et al. 2001) was analyzed both individually and docked with the rest of the protein in 
order to identify the edge residues that appeared capable ofundergoing ~-bonding. This model 
was then compared with the crystal structures of hemopexin (Faber et al. 1995), gelatinase 
(Gohlke et al. 1996), and collagenase (Gomis-Ruth et al. 1996) homologues which do not display 
intermolecular ~-bonding behavior. 
The first step in the structural analysis was 
the identification of edge residues on the ~-
propeller structure of the central domain. The 
highlighted sequences (Fig. 5) are the proposed 
edge residues for this domain of the protein. For 
the upper left strand of vitronectin, the identified 
amino acid sequence is -Gly-Thr-Arg-Gln-Pro-
GIn. Proceeding clockwise around the molecule, 
the identified sequence for the upper right strand is -Ser-Gln-Glu-Glu-Cys-Glu-Gly-Ser. The 
sequence for the lower right strand is -Gly-Val-Leu-Asp-Pro-Asp-Tyr-Pro-Arg-Asn-. For the 
lower left strand, the identified sequence is -Ala-Val-Arg-Pro-Gly-Tyr-Pro-Lys-Leu-Ile. 
In terms ofnegative design found in natural ~-sheet proteins, several predictions can be 
made about the polymerization ofvitronectin based on the identified structural features and 
amino acid sequences. Examination of the upper left strand ofvitronectin shows that it contains 
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Fig. 5. The proposed structure for the central 
domain ofvitronectin with the identified edge 
residues colored in yellow. The assigned strands for 
the respective blades are shown. 
none of the structural motifs identified by the Richardson study (including bulges, shielding, and 
short length) that would be predicted to inhibit self-association. These findings are corroborated 
by the analysis of the amino acid sequence which shows the presence of a single charged species 
(arginine) and one proline. 3-D analysis of this strand with Insight II, however, shows that this 
proline does not induce a bulge that would appear to greatly disrupt potential ~-sheet 
interactions. The charged residue is not at a noticeably "low" point within the molecule where it 
would be significantly buried by further intermolecular interactions. This analysis concludes that 
this portion of the structure lacks most negative design features and would predict that it could 
promote the formation ofmultimeric structures. 
For the upper right strand ofthe protein, structural observation immediately shows a 
predominant bulge at the cysteine residue in the chain. The sulfhydryl group of this residue is 
responsible for the attachment of the C-terminal domain in the docked structure. A chemical 
analysis of this region of the molecule also shows that it contains three negatively charged 
residues (glutamate) that flank the cysteine bulge. This locates the charges at a low point in the 
chain where they would be buried by further ~-sheet interactions. This segment of the protein 
contains both of the two most prevalent forms ofnegative design that have been well established 
as breakers of ~-bonding. It is therefore predicted that this region would not participate heavily in 
intermolecular ~-sheet polymerization. 
Many of the same structural features observed in the upper right strand ofvitronectin are 
also seen in the lower right strand, namely a predominant bulge in the center of the chain. This 
region also has three charged residues (aspartate, arginine), two ofwhich flank the proline bulge. 
Because this region of ' the protein contains both of the primary negative design features, it is 
predicted to be unlikely to participate in intermolecular self-association. 
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Structural analysis of the lower left strand of vitronectin indicates that this may be a 
likely candidate for polymerization. There are no visible bulges, turns, or other structural 
hindrances. Although this region of the molecule does contain two charged residues (arginine, 
lysine), they do not conform to negative design observations as they do not appear to be 
localized at particularly low points within the molecule. This would argue that they do not inhibit 
the formation of ~-bonds. This region also contains two prolines, but does not appear to be 
highly distorted. As it lacks both of the predominant features ofnegative design, it is likely that 
this region may also participate in ~-sheet polymerization. 
An analysis of the location of the central 
domain edge residues on the holistic model 
predicted by small angle x-ray scattering 
measurements supports the initial conclusions for 
the likelihood of ~-sheet polymerization. As shown 
in Figs. 6-8, the edge residues form a belt around the 
outside edge of the lower lobe of the protein. It is 
interesting to note that this leaves the edge strands in 
Fig. 6. Shows the holistic structure of the 
vitronectin protein. The N-terminal domain is 
colored in yellow, the middle domain in blue, 
and the C-terminal domain in purple. The red 
segments are the proposed edge residues for the 
central domain. Note how they appear to form 
a belt around the molecule. 
a position where they may participate in 
intermolecular interactions, and that there appears to 
be partial shielding by the c-terminal domain. 
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Fig. 7. Tbis shows the location of the identified 
residues (separated into strands) relative to the 
bolistic vitronectin protein 
Fig.9. Tbis shows a comparison oftbe structural 
bomology between tbe middle domain of vitronectin and 
gelatinase A, collagenas~3, and bemopexin. Tbe 
identified edge residues for eacb structure are marked in 
yellow. 
Fig. 8. This shows a 3600 rotation of tbe vitronectin protein. 
The N-terminal domain is yellow, tbe middle domain is 
blue, and the C-terminal domain is purple. Tbe red 
segments are tbe proposed edge residues for tbe central 
domain. Note tbe formation oftbe band around the 
molecule. 
It has been observed that the proteins on 
which the structure of vitronectin was based do 
not undergo in vivo polymerization. The 
structures of each of these proteins were aligned 
(Fig. 9) based on obvious features and general 
folding patterns in order to examine the 
differences between them and gain some insight 
into the mechanism ofpolymerization for 
vitronectin. Although the sequence homology is 
not obvious (Table 1), structural analysis and individual sequence analysis do yield some 
patterns ofnegative design. 
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Table I. Edge Residues for Vitronectin and Homologous Proteins By Strand 
Protein Upper Left Lower Left Upper Right Lower Right 
Vitronectin GTRQPQ AVRPGYPKLI SQEECEGS GVLDPDYPRN 
Gelatinase A KSVKFG RDKPMGPL KKMDPGFPKL TLERGYPKP 
Collagenase-3 NRIVRVM VDAELFL HIMDKDYPRL YDILEGYPKK 
Hemopexin AKNLQPQ GWHSWP ATWTEL GYTLVNG'r PKR 
Key: 
• = Positive Charge 
• = Negative Charge 
• = IJ-bulge 
For gelatinase A, the structure on which the accepted model for vitronectin has been 
based, many of the observations remain the same. There are two predominant p-bulges in the 
upper and lower right strands of the protein. The upper right strand contains four charged 
residues (lysine, aspartate). The aspartate residue immediately adjacent to the proline bulge 
would react unfavorably to p-sheet bonding. The lower right strand of gelatinase contains a bulge 
and three charged residues (arginine, glutamate, lysine). Thus, these two regions exhibit both of 
the primary negative design features indicated by the Richardson study to disfavor p-sheet 
polymerization. 
In comparison with vitronectin, the upper left strand ofgelatinase contains two positively 
charged residues instead ofone. The lower left strand contains three charged residues (arginine, 
aspartate, lysine) and two prolines. While these observations are inconclusive for a determination 
about possible polymerization based on negative design, the subtle differences may be enough to 
inhibit intermolecular p-sheet interactions. 
An initial structural analysis of collagenase-3 indicates the same structural barriers 
observed in vitronectin and gelatinase A. The upper right strand contains a p-bulge that is 
flanked by two charged residues (arginine, aspartate), and two additional charges (histidine, 
lysine). This is a classic and predominant example ofnegative design. The lower right strand has 
a bulge and four charged residues (aspartate, glutamate, lysine). In this case, it is likely that the 
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extreme bulge alone is sufficient to break potential ~-polymers. The lower left portion of 
collagenase-3 (although lacking bulges) contains two charged molecules (aspartate, glutamate). 
Again, these last two observations are inconclusive in terms of negative design, but the structural 
subtleties (i.e. charge differences, etc.) may prove enough to inhibit further interaction. 
Finally, the structural model presented for hemopexin least resembles that of vitronectin 
and provides the most inconclusive results for polymerization predictions based on negative 
design. The upper right strand is the only one of the four structures found not to contain a ~­
bulge. Although there may be some shielding by the loop that overhangs this portion of the 
molecule, and it contains one charged residue (glutamate), there is not enough data here to 
support the conclusion that this inhibits ~-bonding. The lower right portion of hemopexin 
contains a predominant ~-bulge which likely prevents further ~-sheet interaction. The lower left 
portion ofhemopexin consists of a snlall bulge, and one potentially charged residue (histidine). 
Although shielding and charged residues contributed by neighboring regions of the molecule 
may playa role in prevention, there is not enough conclusive evidence to make reliable 
predictions regarding ~-sheet polymerization based on negative design. The upper left portion of 
hemopexin is more distorted in comparison with the structure ofvitronectin, and contains a 
charged residue (lysine) as well as one proline residue. It is predicted that this proline in 
conjunction with the charged molecule may introduce enough negative design within this region 
to inhibit polymerization. 
Site Directed Mutagenesis-Based on the predictions made by the analysis of the 
structural model of the central domain, it was decided that two positively charged lysine residues 
would be inserted as this was expected to have the least impact on overall protein folding. 
Furthermore, this type of incorporation has previously been demonstrated to interfere with the 
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formation of intermolecular ~-
K 
Select Point Mutations 
sheet bonds (Wang et al. 2002). 
The sequences for the upper left 
strand and lower left strand are ­
Gly-Thr-Arg-Gln-Pro-Gln- and ­
Ala-Val-Arg-Pro-Gly-Tyr-Pro-
K Lys-Ile- respectively. For the 
Fig. 10. Shows the location of the inserted lysine residues in upper left strand it was decided to 
terms of the structure of the central p-propeller domain. 
replace glutamine 331 with a 
lysine. This places the charged residue towards the middle of the strand and avoids replacing 
existing charges and a proline which would be expected to have a fairly significant impact on 
protein folding. For the lower left strand, it was decided to replace glycine 191 with a lysine. 
Likewise, this places the charged residue towards the center of the strand and should have a low 
impact on overall protein folding. Successful incorporation of these residues was confrrmed by 
sequencing data. 
Fig. 11. Sequencing data confirming Fig. 12. Sequencing data confirming 
correct incorporation of primer # 1 for the correct incorporation of primer #2 
the upper left strand. Mutated for the lower left strand. Mutated 
residues are marked with asterisks. residues are marked with asterisks. 
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SDS-PAGE and Western Blot - Wild Type 
Fig. 13 SDS-PAGE and Western Blot performed on 
wild type vitronectin expressed using the 
Baculovirus expression system. The band on the left 
is the protein isolated from the media, the band on 
the right is the standard indicating a size of about 
67kD. 
SDS-PAGE and Western Blot - Mutant 
Fig. 14. SDS-PAGE and Western Blot performed on 
mutant vitronectin expressed using the Baculovirus 
expression system. The band on the left is the protein 
isolated from the cells, the band on the right is a 
control. 
Protein expression and analysis-Previous 
studies from this lab have confirmed the production 
ofwild type vitronectin by the Baculovirus 
expression system and have demonstrated the 
presence of the protein in the media from which it 
can be isolated (Gibson et al. 2001). In the first 
expression experiment, these results were 
reproduced using the wild type pFastBac expression 
vector (Fig. 11). The relatively sharp band indicates 
production ofprotein around 67kD which is 
consistent with the expected size for vitronectin. 
The second experiment confirmed the successful 
production of the vitronectin mutant protein and 
demonstrated its presence within the cells (Fig. 12). 
It appears that the protein is not secreted into the 
media in large enough quantities to be detected by a 
Western Blot, but previous experience with this expression system has indicated that this may be 
a result of a low titer viral infection rather than protein expression errors. Viral amplification 
experiments are currently underway and it is expected that a higher titer infection will result in 
protein transport to the media as our previous results have demonstrated. 
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Summary and Future Direction 
The identification and characterization of the edge residues of the central domain of 
vitronectin were successful and raise some interesting ideas. The primary conclusion to be 
drawn from the first part of this study is that the two most likely regions for ~-sheet 
polymerization to occur are the upper and lower left strands ofvitronectin. Moreover, the 
structural models show that these edge residues form a band around the outer portion ofthe 
molecule that is not inhibited by other regions of the protein. This is encouraging as it further 
suggests the possibility of ~-sheet polymerization occurring at these sites. 
The mutagenic studies demonstrate the successful production of the mutant vitronectin 
protein using the Baculovirus expression system. Confinement of the protein to the cell fractions 
is most likely a result of a low viral titer infection, however, another possibility to contend with 
may be protein folding anomalies. Subsequent experiments are being repeated with the primary 
aim of increasing viral titer in order to analyze the effects ofmutation on the folding and 
expression ofvitronectin. There are also many other ongoing efforts in this lab to address the 
mechanism behind the self-association ofvitronectin. Namely, a chimeric protein is being 
created by exchanging the central domain ofvitronectin with its hemopexin and gelatinase 
counterparts. This will provide more conclusive evidence as to whether or not the self­
association of vitronectin is actually mediated by intermolecular ~-sheet interactions in the 
central domain of the protein. 
With the information generated by this project, the lab is now poised to directly test the 
hypothesis that mutations may be used to introduce negative design features that inhibit self­
association ofthe virtonectin protein. This data narrows the possible targets to a select few amino 
acid residues, and provides several suggestions for future studies. To date, few studies have been 
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performed to directly show that negative design features may be introduced to disrupt 
intermolecular associations of proteins through ~-sheet polymerization. This work helps to 
expand the body of knowledge in this area, and serves as a good example of the use of 
mutagenesis to study the structure/function relationships in protein self-association. 
- 24­
References 
Bloemendal, HJ., De Boer, HC., Koop, EA., Van Dongen, AJ., Goldschmeding, R. Landman, 
WJ., Logtenberg, T., Gebbink:, MF., Voest. EE. 2004. Activated vitronectin as a target for 
anticancer therapy with human antibodies. Cancer Immunol. Immunother. 53: 799-808. 
Chen, S., Spiegelberg, B. D., Lin, F., Dell, E. J., and Hamm, H. E. 2004. "Interaction of G~'V 
with RACK1 and other WD40 repeat proteins." Journal ofMolecular and Cellular 
Cardiology. 37: 399-408. 
Cherney, R.C., Honan, M.A., Thiagarajan, P. 1993. Site-Directed mutagenesis of the arginine­
glycine-aspartic acid in vitronectin abolishes cell adhesion. J BioI Chem 268: 9725-9729. 
Declerck, PJ., De Mol, M., Alessi, MC., Baudner, D., Paques, EP., Preissner, KT., Muller­
Berghaus, G., Collen, D. 1988. Purification and characterization of a plasminogen 
activator inhibitor 1 binding protein from human plasma. Identification as a multimeric 
form ofS protein (vitronectin). J BioI Chem 263: 15454-15461. 
Deng, G., Royle, G., Wang, S., Crain, K., Loskutoff, D.J., 1996. Structural and functional 
analysis of the plasminogen activator inhibitor-1 binding motif in the somatomedin B 
domain ofvitronectin. J BioI Chem 271: 12716-12723. 
Faber, H. R., Groom, C. R., Baker, H. M., Morgan, W. T., Smith, A., and Baker, E. N. 1995 
"1.8 A crystal structure ofthe C-terminal domain of rabbit serumhaemopexin." 
Structure 3(6), 551-559. 
Gibson, AD., Peterson, CB., 2001. Full-length and truncated forms of vitronectin provide insight 
into effects ofproteolytic processing on function. Biochim Biophys Acta. 
9; 1545(1-2):289-304. 
Gohlke, D., Gomis-Ruth, F. X., Crabbe, T., Murphy, G., Docherty, A. J. P., and Bode, W.-P. 
1996 "The C-terminal (haemopexin-like) domain structure of humangelatinase-A 
(MMP2): structural implications for its function." FEBS Lett 373, 126-130. 
Gomis-Ruth, F. X., Gohlke, M., Betz, M., Knauper, V., Murphy, G., Lopez-Otin, C., and Bode, 
W. 1996 "The helping hand of collagenase-3 (MMP-13): 2.7A crystal structure of its C­
terminal haemopexin-like domain." J. Mol. BioI. 264, 556-566. 
Hom, NA., Hurst, GB. Mayasundari, A., Whittemore, NA., Serpersu, EH., Peterson, CB. 2004. 
Assignment ofthe four disulfides in the N-terminal somatomedin B domain of native 
vitronectin isolated from human plasma. J BioI Chem 279: 35867-35878. 
Ishikawa-Sakurai, M., Hayashi, M. 1993. Two collagen-binding domains ofvitronectin. 
Cell Struct Funct 18: 253-259. 
- 25­
Kirschner, DA., Abraham, C., Selkoe, DJ., 1986. X-ray diffraction from intraneuronal paired 
helical filaments and extraneuronal amyloid fibers in Alzheimers disease indicates 
cross-beta formation. Proc Natl Acad Sci USA. 83: 503-507. 
Liang, OD., Maccarana, M., Flock, JI., Paulsson, M., Preissner, KT., Wadstrom, T. 1993. 
Multiple interactions between human vitronectin and Staphylococcus aureus. 
Biochim Biophys Acta 1225: 57-63. 
Liang, OD., Preissner, KT., Chhatwal, GS. 1997. The hemopexin-type repeats ofhuman 
vitronectin are recognized by Streptococcus pyogenes. Biochem Biophys Res 
Commun. 234: 445-449. 
Mayasundari, A. Whittemore, NA, Serpersu, E. Peterson, CB. 2004. The solution structure 
of the N-terminal domain ofhuman vitronectin. J BioI Chem. 279: 29359-29366. 
Minor, KH., Peterson, CB. 2002. Plasminogen activator inhibitor type 1 promotes the self­
association of vitroncetin into complexes exhibiting altered incorporation into the 
extracellular matrix. J BioI Chem 277: 10337-10345. 
Minor, KH., Schar, CR., Blouse, GE., Shore, JD., Lawrence, DA., Schuck, P., Peterson, CB., 
2005. A mechanism for assembly of complexes of vitronectin and plasminogen activator 
inhibitor-1 from sedimentation velocity analysis. J BioI Chem 280: 28711-28720. 
Podor, TJ., Shaughnessy, SG., Blackburn, MN., Peterson, CB. 2000. New Insights into the Size 
and Stoichiometry of the Plasminogen Activator Inhibitor Type-1'Vitronectin Complex. 
J BioI Chem 275: 25402-25410. 
Reuning, U., Magdolen, V., Wilhelm, 0., Fischer, K., Lutz, V., Graeff, H., Schmitt, M., 1998. 
Multifunctional potential of the plasminogen activation system in tumor invasion and 
metastasis. Int. J OncoI. 13: 893-906. 
Richardson, JS., Richardson, DC. 2002. Natural ~-sheet proteins use negative design to avoid 
edge-to-Edge aggregation. PNAS. 99:2754-2759. 
Sieffert, D., Loskutoff, DJ., 1991. Kinetic analysis of the interaction between type 1 
plasminogen activator inhibitor and vitronectin and evidence that the bovine inhibitor 
binds to a thrombin-deprived amino-terminal fragment of bovine vitronectin. Biochem 
Biophys Acta 1078: 28-30. 
Springer, T. A. 2002 "Predicted and experimental structures ofintegrins and ~-propellers." 
Curro Opin. Struct. BioI. 12, 802-813. 
Stricker, T. P., Dumin, J. A., Dickeson, S. K., Chung, L., Nagase, H., Parks, W. C., and Santoro, 
S. A. 2001 "Structural analysis of the a2 integrin I domainlprocolloagenase-1-(matrix 
metalloproteinase-1) interaction." J BioI. Chem. 276,29375-29381. 
- 26­
Suzuki, S., Pierschbacher, MD., Hayman, EG., Nguyen, K. Ohgren, Y. et al. 1984. 

Domain 

structure ofvitronectin. J Bioi Chern 259: 15307-14. 

Wang, W., Hecht, MH., 2002. Rationally designed mutations convert de novo amyloid-like 
fibrils into monomeric beta-sheet proteins. Proc Natl Acad Sci USA. 99:2760-5. 
Xu, D., Baburaj, K., Peterson, CB. 2001. Model for the Three-Dimensional Structure of 
Vitronectin: Predictions for the Multi-Domain Protein from Threading and Docking. 
Proteins: Structure, Function, and Genetics. 44:312-320. 
Zhuang, P. Blackburn, MC., Peterson, CB., 1996. Characterization of the Denaturation and 
renaturation of Human Plasma Vitronectin. I. Biophysical Characterization of Protein 
unfolding and Multimerization. J Bioi Chern 271: 14323-14332. 
- 27­
Kevin C. Walters 

Summer Internship Progress Report 

Advisor: Dr. Cynthia Peterson 

9/0112005 
Introduction 
Vitronectin is a nlultifunctional glycoprotein found in both the circulation and the 
extracellular matrix (ECM). Through its capacity to interact with a wide variety of 
ligands it helps to mediate several key physiological processes including coagulation, cell 
adhesion and migration, tumor metastasis and tissue remodeling, and immune system 
response. An interesting feature of the protein is its ability to adopt different functional 
forms presumably as a result ofvarying physiological conditions. The monomeric form 
ofvitronectin is found in the circulation where it helps to regulate proteolytic cascades. 
Conversely, a multimeric form ofvitronectin is found in the ECM where it helps to 
regulate pericellular proteolysis as well as cell adhesion and migration. The process by 
which the monomer assembles into higher order complexes remains relatively 
uncharacterized, but is believed to be mediated by the binding of vitronectin to 
plasminogen activator inhibitor type-I (PAl-I). 
Since its discovery in 1967, extensive research has been performed with the 
primary focus of characterizing the binding sites for various ligands. Although vitronectin 
has not been successfully crystallized, advances in technologies with biological 
application have proved useful in studying how the structure of the protein relates to its 
function. Combined computational analyses and NMR measurements have produced 
structural models for the three domains of vitronectin. The central domain is ofparticular 
interest because it was shown to contain extensive p-sheet content organized into a four 
bladed propeller-type structure. It is believed that this domain ofvitronectin is integral in 
the formation ofhigher order complexes through intermolecular propagation of its p­
sheets. 
1 
In other studies, it has been observed that ~-propellers are prominent structures 
present during the intermolecular associations ofproteins. Some well-known examples of 
this include the WD-40 structures in signal transduction, ~-propeller domains in matrix 
metalloproteinases, and the head regions of integrins that recognize ECM ligands. These 
examples further suggest the central domain of vitronectin as a mediator of 
intermolecular associations. The N-terminal and C-terminal domains also have been 
eliminated as possible candidates for higher order complex formation. The N-terminal 
somatomedin B (SMB) domain has been isolated and shown to be monomeric and stable 
under physiological conditions. Also, earlier work with the folding and denaturation of 
vitronectin has shown that binding of the heparin ligand to the C-terminal domain did not 
disrupt the formation of higher order complexes. 
The structures of several homologous proteins with a four bladed propeller motif 
have been solved, but these naturally occurring ~-sheet proteins typically do not associate 
into higher-order oligomers. This suggests that in these cases regulatory features must 
exist which inhibit ~-sheet interaction in favor of the monomeric protein. Extensive 
analysis of ~-sheet proteins performed by Richardson et aI. has resulted in a set of rules 
for ~-strands that govern the formation of more extensive intra- or intermolecular 
structures. They suggest that certain features of~ edge strands may be responsible for 
preventing propagation via hydrogen bonding to additional ~-strands. This analysis was 
used as a general guideline to contrast the edge residues in ~-propeller structures for 
vitronectin, hemopexin, and homologues in order to predict the features responsible for 
the association behavior observed in vitronectin. The goal of this project is to test these 
predictions via mutagenesis studies in which entire domains are substituted followed by 
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site directed mutagenesis to further define the specific edge residues involved. This will 
provide a valuable insight into the mechanistic aspect of the formation ofvitronectin 
complexes. Furthermore, this study serves as an important test of the notion that specific 
structural features may serve as a "negative design" to inhibit further ~-sheet association 
and distinguish central and peripheral strands in ~-propeller structures. 
Experimental Outline 
For these experiments, a drosophila expression system will be used in lieu of the 
baculovirus expression system with the hope ofgenerating a greater level of expression 
than typically observed. In order to create the chimeric or mutated protein, the gene for 
vitronectin will first be amplified through a polymerase chain reaction (PCR) to produce 
a high yield ofDNA fragments. The general protocol for the PCR reaction is as follows: 
mixed into a small test tube are 1 JlI pcDNA4/ssvn vitronectin template, 3JlI MgCI buffer 
(with four different concentrations), 3JlI dNTPs, 3JlI forward primer, 3Jll reverse primer, 
1JlI ofTaq DNA polymerase (diluted 1 :4), and 16JlI ofwater. This is then placed into a 
thermocycler under the following run conditions: 94°C for two n1inutes, 94°C for thirty 
seconds, 55°C for thirty seconds, 72°C for thirty seconds, and 72°C for two minutes. The 
process is allowed to repeat for twenty-five cycles after which time a yield will be 
determined via gel electrophoresis. After determining which concentration of buffer 
produced the highest yield of vitronectin gene fragments, they will be ligated into the 
cloning vector PCR2.1 from Invitrogen's T A cloning kit. For the ligation, three reactions 
are set up with 1 :2, 3 :2. 5:2 ratios ofPCR product to cloning vector. In addition, 1 JlI of 
lOX ligation buffer, lfJL T4 DNA ligase, and 5fJI ofwater are added to each reaction. 
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They are placed in a 15°C water bath overnight. The ligation products are then 
transformed into competent DH-5a E. coli cells and spread onto plates coated with X-gal 
and IPTG. The IPTG serves as an inducer of the lac operon and the X-gal helps to 
indicate colonies that have taken up the PCR gene. The vitronectin inserts into the middle 
of a gene coding for p-galactosidase which can cleave X-gal to form a blue product. 
Thus the colonies that have successfully taken up the gene are white while the others are 
blue. Several white colonies are grown up and the plasmid DNA is purified with the 
Qiagen mini prep kit. The plasmid is then digested with the BglII and Agel enzymes 
under the following conditions: 3JlI DNA, O.5JlI BglII, O.5JlL Agel, IJlI Buffer #2, and 
5JlI ofwater. This mixture is incubated at 37°C for one hour after which time the products 
are separated on an agarose gel and the vitronectin fragment is purified with the Qiagen 
gel extraction kit. Likewise, the expression vector is also digested and purified under the 
same conditions. Finally, the two products are ligated together to complete a cloned 
expression vector. This expression vector will then be used to induce the S2 drosophila 
cells to produce wild type vitronectin as a test for yield with this particular expression 
system. Finally, the expression vector can be used as a template to create a chimeric 
protein via domain swapping with vitronectin homologues and as a template for site 
directed mutagenesis. The analysis ofthe oligomerization status of the protein will be 
performed with a western blot. 
Progress towards Research Aims 
This work was initiated by comparing the homologous p-propeller domains of 
vitronectin, hemopexin, collagenase, and gelatinase with a primary focus on differentially 
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charged edge strands and the presence of p-bulges, two predominant features noted in the 
Richardson study that may prevent oligomerization. Based on this comparative analysis, 
work began to create a recombinant expression vector for the drosophila expression 
system. During this process, however, there were many technical difficulties resulting in 
changes to the cloning strategy. 
First, in order to create the recombinant expression vector, stock vitronectin 
template and primers were used as described in the experimental method. When this 
failed to yield usable plasmid DNA, a blunt ligation reaction was attempted. This was 
performed in the same manner as previously described, but bypassed ligation into the 
cloning vector peR2. 1. Instead, the peR products were digested, purified, and inserted 
directly into the expression vector. Again this failed to produce any usable recornbinant 
plasmid DNA. Following this second failure, a series ofcontrol reactions were performed 
in order to pinpoint the defective step in the cloning process. Initially it was believed that 
the problematic area was a contaminated reagent. With this in mind, all experiments were 
repeated with new reagents, paying particular attention to sterile technique and the 
possibility of cross contamination. Again they failed to create the desired product. 
Finally, through analysis of restriction digests and sequencing information, it was 
determined that the source oferror was the stock of primers used for the peR reaction 
which potentially exhibited weak or non-specific binding and hence prevented the 
amplification of the desired product. Thus, new primers were designed with the help of 
the DNAstar computer program. To date, these primers have proved effective and all 
currently attempted steps have produced successful results. 
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Future Outline 
After overcoming the initial problems with the cloning strategy, the future plan is 
to continue with the project as outlined in the experimental methods portion of this paper. 
To date, the vitronectin gene is being ligated into the vector for the drosophila expression 
system with results expected in a few days. We are also taking advantage of the ability to 
express vitronectin in a variety of host systems by concurrently using the baculovirus 
expression system to help ensure the production of a usable vector which can then be 
mutated as desired. Chimeric proteins containing replacements for the entire ppropeller 
domain will be generated as described and tested for known vitronectin functions 
including heparin binding, integrin binding, uP AR binding, and P AI-I binding and 
stabilization. The role of specific amino acid residues in the oligomerization process will 
be analyzed through site-directed mutagenesis techniques. Mutations that disfavor the 
formation of the multimer will be screened for using native PAGE and western blotting 
with anti-vitronectin antibodies. It is important here to remain cautious and anticipate the 
problems that may yet occur with this mutagenesis experiment. For one, the replacement 
of an entire domain of vitronectin may disrupt the normal packing and folding of the 
protein. Also, these changes may disrupt the secondary P AI -1 binding sites in vitronectin 
which may be problematic as it is the interaction with P AI-I which is believed to induce 
the formation of multimeric vitronectin complexes. Furthermore, the evaluation of the 
oligomerization status of the protein is likely not to be as straightforward as running a 
Western blot. These problems, however, will be addressed on a case-by-case basis as the 
project progresses. 
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ABSTRACT 

This research uses an upper bound on the radiation doses received by astronauts 
in space by using the data available of the large Oct 19, 1989 solar particle event. Organ 
doses and dose equivalents are estimated using BR YNTRN, a space radiation transport 
code developed at NASA Langley Research Center which transports incident solar 
protons and their reaction products (protons, neutrons, 2H, 3H, 3He, and 4He) through 
the various areal densities of aluminum and then through an additional quantity of water1 • 
The calculated doses and dose equivalents as a function of water depth, obtained from the 
assumed input SPE spectrum, are then folded with the body organ self-shielding 
distributions obtained from the CAM model to yield dose and dose-equivalent estimates 
for the organs of interest. By using various lower energy cutoffs' in the calculations, 
organ doses and dose equivalents are extracted and modeled as a function of energy and 
aluminum density using MATLAB; as a result, skin, eye, and blood forming organ doses 
and dose equivalents are available for any particular particle energy for a variety of 
aluminum densities. Additionally, this research determines the minimum aluminum 
density needed to stay within the confines of the ICRP 60 dose recommendations to be 
approximately 25 glcm2• A large number of figures depicting the doses and dose 
equivalents as functions of particle energy and aluminum density are included in the 
appendix. 
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1.0 INTRODUCTION 

1.1 BACKGROUND 

Within the next couple of decades, manned missions to Mars will be undertaken. 
However, before any foray into space past the moon is undertaken, research must be done 
that can develop methods of estimating the effects of galactic cosmic rays (OCRs), 
energetic solar particle events (SPEs), and other radiation phenomena on astronauts and 
on-board technology. 
Chronic exposures to the background galactic cosmic ray (OCR) environment is 
mainly a matter of concern for stochastic effects, such as the induction of cancer with 
subsequent mortality in many cases, and late deterministic effects, such as cataracts and 
possible damage to the central nervous system. The actual risks of cancer induction and 
mortality for the very important high-energy heavy ion component of the OCR spectrum 
are essentially unknown, but are the subject of numerous, current radiobiological 
investigations using laboratory beams and animal and cell culture systems. 
The earth's magnestosphere shields earth and spacecraft within it from charged 
particles; however, once outside of the magnestosphere, SPEs become of concern. Large 
SPEs, although uncommon, are dangerous to organisms and onboard electronics. Large 
fluxes of energetic particles, namely protons and alpha particles, often have very high 
energies and can be extremely detrimental to organisms, spacecraft, and space missions. 
This research focuses on providing organ doses and dose equivalents from the Oct 19, 
1989 SPE as a function of aluminum density and particle energy. 
1 
1.2 STATEMENT OF THE PROBLEM 
With SPEs, the individual dose contributions of energetic particles of differing 
energies shielded by various aluminum densities are not easily calculated or known. 
These values can be extracted and tabulated with varying aluminum thicknesses using the 
computational code BRYNTRN and the additional codes DOSEFIT and SUMDLOC. 
Thirteen different aluminum areal densities are considered, each with 20 different water 
depths. Seventeen different lower energy cutoffs are used on the energy spectrum so that 
the doses in each of these energy bands can be extracted with sufficient resolution. These 
results identify the combinations of particle energy and aluminum depths that fall within 
the ICRP 60 recommended occupational dose limits. 
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2.0 SPACE RADIATION ENVIRONMENT 

2.1 INTRODUCTION 

The high-energy particles that permeate space are of acute concern in planning 
missions pass the Earth's magnetosphere. Solar particle events in particular, are of 
immense concern due to a periodic occurrence and large range in energy. Particle 
energies ranging from several Me V to many orders of magnitude in Ge V are quite 
possible. Although particles of extremely high energy are rare, they can penetrate 
appreciable shielding thickness and have a high linear energy transfer (LET), causing 
much energy to be imparted in traversing shielding or tissue. This results in undesirable 
secondary particles and radiation fields which cause additional damage. Because of their 
energy and violent nature of interaction with matter, solar particle events pose a 
significant risk to space crews on interplanetary missions. 
2.2 SOLAR PARTICLE RADIATION AND SUNSPOT ACTIVITY 
During a period of maximum sunspot activity of the sun, particle emissions are 
marked by large fluxes of energetic ions and increased plasma emissions. During this 
increased population of energetic ions, human space activity is retarded due to satellite 
and communication affects when solar plasma interacts with the Earth's magnetosphere 
and upper atmosphere and the increased risk of tissue damage.4 
2.3 ENERGETIC SOLAR PARTICLE EVENTS 
Solar particle events are characterized using several different terms, chiefly flux, 
fluence, and spectral hardness. Flux can either be described by integral or differential 
quantities. Integral flux is the number of particles/cm2/sr/s above some energy, whereas 
3 
differential flux is the number of particles/cm2Isrls/MeV2. Fluence is time-integrated flux 
and is very useful because it is used to describe the number of particles observed during 
an event. This characterizes the total energy from the event and is useful in determining 
dose quantities. Spectral hardness and softness describe the relationship between fluence 
and energy. A hard spectrum has little decrease in particle population as energy 
decreases. In soft spectra, fluence drops rapidly as energy energy increases. Essentially, 
these describe the number of energetic particles in which one is concerned. 
2.4 SOLAR PROTON EVENTS 
Proton flux and fluence characterize solar proton events. Some correlation 
between proton event frequencies observed near Earth and solar activity exist, but there is 
no distinct pattern in proton even occurrence.4 Stuart and Shea6 have performed 
statistical analyses of three recent solar cycles (19,20, 21) in an effort to determine the 
frequency of large events. They found that a log -normal distribution characterizes the 
proton event fluence during periods of maximal solar activity; however, very large SPEs 
are less frequent than expected using the log-normal model, implying that the presence of 
an upper bound in frequency. 
2.5 INTERPLANETARY MISSION PLANNING 
As described earlier, the two principal radiation dose contributors in space are the 
OCR and SPEs. The OCR spectrum is highest during the solar cycle minimum, as seen in 
figure 2.5.1 
4 
Figure 2.5.1. OCR fluxes for representative ions in solar cycle. 
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This poses a difficult situation for mission planning due to the contrary behavior 
of SPEs: Smart and Shea4 have shown that the probability for a large SPE is highest just 
before or after the maximum of the solar cycle. Therefore, mission scheduling is 
unresolved and further research needs to be done in this area. Solar particle events can 
occur at any time and come in a wide variety of sizes; unfortunately, their sizes usually 
are not known until they have already terminated. Because of this, models must be built 
from a worst case scenario. 
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3.0 SPACE RADIATION TRANSPORT THEORY 

3.1 BACKGROUND 

Interplanetary magnetic fields caused solar particles to spiral along their trajectory 
away from the sun such that their path will resemble a braided rope4, The spread of the 
particles is so large that they appear outside the Earth's magnetosphere as an isotropic 
source incident on the spacecraft. After interaction, the energy of these particles is still so 
high that they continue in straight-lines; therefore, a straight-line approximation using the 
I-D Boltzman equation can be utilized in predicting particle population density, 
3.2 HIGH ENERGY ApPROXIMATION 
BRYNTRN, a deterministic coupled neutron-proton transport computer code 
characterizes the primary and secondary interactions of solar particles and galactic 
cosmics rays3. It transports incident solar protons and their reaction products (protons, 
neutrons, 2H, 3H, 3He and 4He ) through any shield material and an additional quantity of 
water. The high-energy nature of the particles allow for a straight-line approximation to 
be made in the Boltzman transport equation to yield the one-dimensional version for 
protons and heavior ions2: 
[~-~S(E)+(]'p(E)]t/Jp(X'E) =l: jfpj(E,E')t/Jj (x, E')dE' , (1)ax ax j E 
The charged particle term (COUIOlllb repulsion) is absent for the neutron analog2 
(2) 
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f pj (E, E') is the differential cross section for elastic and inelastic collision processes . 
¢j(x,E') is the flux ofl type ions moving in the direction x with energy E' (MeV). 
CTp(E) is the macroscopic absorption cross section (cm- I ). The as(E)¢p is the Coulomb 
ax 
interaction term and a¢ represents the net transfer of particles into and out of the 
ax 
material. CTp (E)¢p (x, E) is the nuclear attenuation term. In comparison to exact 
analytical benchmarks solutions for continuous space proton input spectrum, BRYNTRN 
has been verified to within 1 percent accuracy3. 
3.3 DOSEIDOSE EQUIVALENT CALCULATIONS 
Doses are calculated using 
00 
DJx,> E) =~ JSi(E')¢i(X,E')dE' (3) 
E 
This provides the dose at some distance x from particles whose energy is greater than ER. 
Ai is the atomic mass number of the colliding nuclei. S(E) is the collisional stopping 
power 
S(E) = 41iNZ2p Zt e
4 
{ In 2mv2 _ p2 __ C } (4)2 mv (1- P2)It Zt 
where Zp is the charge of the particle, N the density of the target molecules, Zt the 
number of electrons per target molecule, m the mass of an electron, v the velocity of the 
particle, P the ratio of the velocity to the speed of light, It the mean excitation energy, 
and C a velocity-dependent shell correction term3. Using the quality factor Q, the dose 
equivalent can be calculated using the following equation: 
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00 
Hj(x,> E) = Ai fQi(E')Si (E')t/Ji (x, E')dE' (5) 
E 
For nuclear recoils produced by incident protons and for target fragments, dose and dose 
equivalents are given by the following equations: 
Dp *(x,> E) =L 
00 
fE/()jp(E')t/Jp(x,E')dE' (6) 
j E 
and 
H p *(x,> E) L 
00 
fE/QFj(E')()jp(E')t/Jp(x,E')dE' (7) 
j E 
where Ej is the average recoil energy of the lh-fragment
2
. For transported neutrons, all 
dose and dose equivalent contributions result from target nuclei recoils or fragments and 
are computed using identical equations3• 
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4.0BRYNTRN 

4.1 BACKGROUND 

BRYNTRN was developed at the NASA Langley Research Center for the 
purpose of estinlating crew dose/dose equivalents from exposure to the space 
environment. It calculates these using a converging, marching algorithm representing 
solutions to the I-D Boltzman transport equation1• It uses a mesh point grid of 70 energy 
points logarithmically distributed so that lower energy particles are more represented that 
higher-energy. Lower bound energy cutoffs had to be carefully selected so that they did 
not lie between the same mesh points. Because of the straight-ahead approximation 
introduced in solving the Boltzman transport equation, BRYNTRN's result compare well 
to advanced three dimensional transport codes and requires much less computational 
time. 
4.2 IMPLEMENTATION 
BRYTRN must be compiled and linked before it can be run. When run, it displays 
a prompt screen asking for the type of simulation (Solar Particle Event), number of 
aluminum depths, number of water depths, etc. It's results are outputted to a specified 
file. The names of these files contained the parameters used in the simulation so that upon 
inspection of the filename, the user knows the data contained within. BR YTRN is 
followed by DOSEFIT, an intermediate program that takes the BRYNTRN output and 
uses aluminum shield files to change the data to a form as a function of water depth and 
aluminum depth. For every BRYNTRN output, DOSEFIT was run for all the different 
aluminum shield thicknesses. SUMDLOC then converted these outputs using organ self­
9 
shielding distributions into the dose and dose equivalent quantities displayed in the tables 
and figures in the results and appendices. The organs of interest are the skin, eyes, and 
blood forming organs. 
10 
5.0 DATA ANALYSIS 

In this research, 13 different aluminum areal densities are considered, each with 
20 different water depths. Most importantly, 17 different lower energy cutoffs are used 
on the energy spectrum so that the doses in each of these energy bands can effectively be 
extracted. The maximum energy used in the spectra is 2500 MeV. The cutoffs are at 0, 
10,20,30,40,50,60,70,80,90,100,110,120,140,160,180, and 200 MeV. The 
aluminum densities used are 1, 2, 3,5, 7, 10, 15,20, 25, 35, 50, 65, and 85 glcm2• The 
water depths used for each of the aluminum densities are 0, 1, 2, 3, 5, 7, 10, 15, 20, 30, 
40, 50, 65, 85, 100, 115, 130, 145, 160, and 175 g. Lastly, each of these water depths are 
folded into the skin, eye, and blood forming organ self-shielding distributions to yield 
doses, dose equivalents, and quality factors for the said organs. 
It is important to note that the values calculated are from the 1989 large solar 
particle event in October 19-29. These serve as a worst-case scenario involving a solar 
particle event developing and exposing deep-space crew members to radiation. 
In a BRYTRN calculation, for a particular aluminum density and water depth, the 
2500 
total dose can be symbolically shown as a function of energy in Dtotal (E) = Jf(E)dE, 
Ell 
where En is the energy cutoff selected; however, the total dose over a particular range is 
not the information sought. The dose contributions between the different energy cutoffs is 
the data valued because it details from which energies the doses originate; therefore, a 
simple change in the integrand will yield the desired technique to extract the dose 
information. 
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En 2500 2500 
For En < En+l' ff(E)dE ff(E)dE - ff(E)dE. 
o o 
En+l 2500 2500 
Similarly, ff(E)dE = ff(E)dE - ff(E)dE. Therefore, 
o 0 ~~ 
~B ~B ~ 
ff(E)dE = ff(E)dE - ff(E)dE. 
~ 0 0 
EnB 2500 2500 ~OO ~oo JSubstituting in, ff(E)dE = ff(E)dE - If(E)dE If(E)dE- if(E)dE . This[
o 
E,,+1 2500 2500 
yields If(E)dE If(E)dE- ff(E)dE. 
En Ell! 
Quality factors are determined using a simple linear interpolation between the 
successive energies for a particular aluminum density. For example, the quality factors 
from 0 < E < 2500 and 10 < E < 2500 MeV are averaged due to their close proximity in 
energy. The quality factor calculated from BRYTRN is the quality factor over the energy 
range of the calculation; as a result, a simple average can be performed because the 
energy intervals averaged over are very small compared to the energy range of 2500 
MeV. 
The result ofBRYTRN is particle flux, dose, and dose equivalents for each of the 
aluminum densities, each with twenty different water depths. A code called DOSEFIT 
takes this output from BRYTRN and the parameters used to run it (number of aluminum 
and water depths) and generates data files containing dose and dose equivalents as a 
function of water depth using different aluminum density data input files. These files 
contain the data on the individual aluminum densities and the water surrogate. Lastly, a 
12 
program, SUMDLOC, developed at NASA Langley, folds the outputs into the organs of 
interest using the skin, eye, and blood fonning organ self-shielding distributions obtained 
from the computerized anatomical man (CAM). 
5.1 SKIN DATA ANALYSIS 
In Tables 1 and 2, the highest absorbed dose occurs when aluminum shielding is 
minimal, 1 g/cm2• For 1 glcm2 , 43.2 % of the total dose in the SPE energy range to 2500 
Me V occurs in energies 20 <E < 30 Me V. This means that for skin, the energies that 
contribute most to absorbed dose are those 20 < E < 30. In energies 0 < E < 20, there is 
zero absorbed dose, indicating that these particles are of no concern and should be 
disregarded in designing shielding systems. The next energy ranges, from 20 < E < 60 
Me V, contribute heavily to the absorbed dose. As expected, when alunrinum density 
increases, the absorbed dose decreases. For each successive aluminum density, the 
maximum energy contributions move down the energy range. For example, with a 
aluminum density of 5 g/C1112, the largest energy contributor is 60 < E < 70 Me V, 
illustrating that higher energy particles will penetrate further in shielding materials than 
lower energy particles. Tables 3 and 4 show the percentage contribution of a particular 
energy range to that particular density's total absorbed dose. The data shows that particles 
with energies from 20 to 90 Me V are the main contributors to absorbed dose. Similar 
tables for dose equivalent (cSv) and quality factor are located in the appendices. 
Beginning with an aluminum density of 20 g/cm2, the total dose falls to 12.15 
cGy.(or 121.5 mGy) With this density, the largest dose contributor is 120 < E < 140 
MeV, with a dose of 4.45 cGy. 
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The ICRP 60 occupational dose limits specify that an individual receive no more 
than 150 mSv to the lens of the eye or 500 mSv to the skin, hands, and feet. Table 13, the 
skin dose equivalents, shows the dose equivalent using an aluminum density of 15 g/cm2 
to be 329.7 mSv. This is the minimum aluminum density that meets the ICRP 60 
specification for skin, hands, and feet. Therefore, this research recommends that 
aluminum have an areal density of at least 15 g/cm2 to meet ICRP requirements; 
however, these occupational exposures could be modified for astronauts and other special 
science personnel. 
14 
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5.1.1 SKIN ABSORBED DOSE TABLES 

Table 1. Skin absorbed dose (cGy) per energy range per aluminum density through 15 
gJcm2 
Skin dose (cGy) Aluminum Densities 
Energy range 10 15 I 
(MeV) 1 g/cm2 2 g/cm2 3 g/cm2 5 g/cm2 7 g/cm2 g/cm2 g/cm2 
O<E < 10 0.0000 0.0000 -0.0044 0.0000 -0.0005 0.0000 0.0000 
10<E<20 0.0000 0.0003 0.0001 0.0004 0.0009 0.0004 0.0003 
20 <E<30 334.4500 0.0037 0.0034 0.0044 0.0034 0.0034 0.0028 . 
30<E<40 187.0600 115.1000 0.0107 0.0102 0.0094 0.0080 0.0066 
40 <E<50 105.4500 127.2500 89.7270 0.0177 0.0166 0.0151 0.0123 
50<E<60 57.7890 57.3920 67.7710 26.3000 0.0728 0.0230 0.0189 
60 <E <70 29.3580 32.4200 35.1690 50.4810 23.4610 0.1667 0.0248 
70<E<SO 11.3950 10.7650 10.6480 12.1550 16.2660 2.7337 0.0159 
SO<E<90 17.0700 15.9540 15.6850 15.7210 17.1850 20.3630 10.0580 
90< E< 100 7.3892 6.2882 5.7755 5.3851 5.3328 5.7283 0.1108 i 
100<E<110 5.9481 5.5972 5.2644 4.5622 4.1858 4.1118 0.8794 
110 <E< 120 4.6441 4.2336 4.0213 3.9335 3.6226 ~ 2.7536 120<E< 140 6.8053 6.2886 5.8578 5.3606 5.1474 4.4457 
140<E < 160 2.3035 2.1838 2.0736 1.8974 1.7863 1.6617 1.3898 
160 < E < lS0 1.7234 1.6272 1.5417 1.4159 1.3489 1.2810 1.0811 
lS0 < E < 200 2.2531 2.1492 2.0486 1.8711 1.7380 1.6167 1.3878 
Sum 773.6387 387.2528 245.5927 129.1155 80.1764 45.7614 22.1876 
g,cm2 
Skin dose (cGy) Aluminum Densities 
Energy range 
(MeV) 
20 
f!/cm2 
25 
f!/cm2 
35 
f!/cm2 
50 
f!/cm2 
65 
f!/cm2 
85 
f!/cm2 
0< E < 10 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
10<E<20 0.0002 0.0002 0.0001 0.0001 0.0000 0.0000 
20<E< 30 0.0022 0.0017 0.0012 0.0006 0.0005 0.0002 
30<E<40 0.0054 0.0044 0.0030 0.0016 0.0012 0.0006 
40 <E< 50 0.0102 0.0084 0.0057 0.0032 0.0022 0.0011 
50 <E<60 0.0156 0.0130 0.0089 0.0051 0.0035 0.0018 
60<E<70 0.0208 0.0173 0.0121 0.0071 0.0049 0.0026 
70 <E< SO 0.0125 0.0105 0.0075 0.0045 0.0031 0.0017 
SO<E<90 0.0342 0.0255 0.0185 0.0115 0.0080 0.0045 
90 <E< 100 0.1108 0.0161 0.0110 0.0071 0.0050 0.0029 
100 < E < 110 0.8794 0.0421 0.0122 0.0079 0.0056 0.0033 
110 < E < 120 2.7536 0.2957 0.0139 0.0088 0.0063 0.0038 
120 < E < 140 4.4457 3.1315 0.1475 0.0202 0.0146 0.0089 
140<E< 160! 1.3898 1.3220 0.5179 0.0136 0.0098 0.0061 
160<E< lS0 1.0811 0.9920 0.8524 0.0374 0.0271 0.0176 
lS0<E<200 1.3878 1.2971 1.1316 0.4592 0.3612 0.2626 
Sum 12.1493 7.1776 2.7435 0.5879 0.4532 0.3176 
Table 2. Skin absorbed dose (cGy) per energy range per aluminum density through 85 
I 
. 
. 
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Table 3. Skin dose percentage contribution per energy range per aluminum density 
th h 15 / 2rougJ g cm 
Skin dose 
percenta2e Aluminum Densities 
Energy range 3 5 7 10 15 
(MeV) 1 gJcm2 2 gJcm2 wcm 2 JI/cm2 JI/cm2 wcm 2 wcm 2 
0< E < 10 0.0% 0.0% 0.0% 0.0% 0.0% i 0.0% 0.0% 
10<E<20 i 0.0% 0.0% 0.0% 0.0% 0.0% i 0.0% 0.0% 
20<E<30 43.2% 0.0 0.0% 0.0% 0.0% 0.0% 0.0% 
30<E<40 24.2% 29.7% 0.0% 0.0% 0.0% 0.0% 0.0% 
40<E<SO 13.6% 32.9% 36.5% 0.0% 0.0% 0.0% 0.1% 
SO<E<60 7.5% ' 14.8% 27.6% 20.4% 0.1% 0.1 0.1% 
60<E<70 3.8% 8.4% 14.3% 39.1% 29.3% 0 0.1% 
70 < E < 80 1.5% 2.8% I 4.3% 9.4% 20.3% 6.0% 0.1% 
80<E<90 2.2% 4.1% 6.4% 12.2% 21.4% 44.5% 45.3% 
90<E<100 , 1~ 1.6% 2.4% 4.2% 6.7% 12.5% 0.5% 
100<E<110 0.8% 1.4% 2.1% 3.5% 5.2% 9.0% 4.0% 
110 < E < 120 0.6% 1.1% 1.6% 3.0% 4.5% 7.0% 12.4% 
120 < E < 140 0.9% 1.6% 2.4% 4.2% 6.4% 10.6% 20.0% 
140<E< 160 0.3% 0.6% 0.8% 1.5% 2.2% 3.6% 6.3% 
160 <E< 180 0.2% 0.4% 0.6% 1.1% I 1.7% 2.8% I 4.9% 
180< E <200 0.3% 0.6% 0.8% 1.4% 2.2% 3.5% 6.3% 
Table 4. Skin dose percentage contribution per energy range per aluminum density 
th h 85 / 2rougJ gJcm 
Skin dose Aluminum 
percentage Densities 
Energy range 25 35 50 !65 85 
(MeV) 20 g/cm2 g/cm2 g/cm2 g/cm2 g/cm2 g/cm2 ' 
o<E < 10 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
10<E< 20 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
20<E<30 0.0% 0.0% 0.0% 0.1% 0.1% 0.1% 
30 <E <40 0.0% 0.1% 0.1% 0.3% 
i 
0.3% 0.2% 
40 < E < 50 0.1% 0.1% 0.2% 0.5% 0.5% 0.3% 
50< E<60 0.1% 0.2% 0.3% I 0.9% 0.8% 0.6% 
60<E<70 0.2% 0.2% 0.4% 1.2% 1.1% 0.8% 
70 <E<80 0.1% 0.1% 0.3% 0.8% 0.7% 0.5% 
80<E<90 0.3% 0.4% 0.7% 2.0% 1.8% 1.4% 
90<E<100 0.9% 0.2% 0.4% 1.2% 1.1% 0.9% 
100 < E < 110 7.2% 0.6% 0.4% 1.3% 1.2% 1.0% 
110 < E < 120 22.7% 4.1% 0.5% 1.5% 1.4% 1.2% 
120 < E< 140 36.6% 43.6% 5.4% 3.4% 3.2% 2.8% 
140< E < 160 11.4% 18.4% 18.9% 2.3% 2.2% 1.9% 
• 160 < E < 180 8.9% 13.8% 31.1% 6.4% 6.0% 5.5% 
180<E<200 11.4% 18.1% 41.2% 78.1% 79.7% 82.7% 
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5.2 EYE DATA ANALYSIS 
The eye data shows that the primary dose contributors for low aluminum density 
thicknesses are in the energies 20 < E < 80 MeV, with the majority from 20 < E < 50 
Me V. At an aluminum density of 20 g/cm2, the largest energy contributors are at higher 
energies, 120 < E < 140 MeV, representing 40.7% of a total absorbed dose of 12.01 cGy. 
U sing the dose equivalent data from the appendices, Table 18 shows the 
minimum aluminum density required to meet the eye requirement is 25 glcm2. This 
results in a 108.0 mSv dose equivalent. The largest energy contributor to this dose is the 
120 < E < 140 energy band, constituting 39.5% of the dose. 
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5.2.1 EYE ABSORBED DOSE TABLES 
Table 5. Eye absorbed dose (cOy) per energy range per aluminum density through 15 
/ 2gJcm 
! 
Eye dose (cGy) Aluminum Densities 
Energy range 2 7 10 15 
(MeV) 1 g/cm2 g/cm2 3 g/cm2 5 g/cm2 g/cm2 g/cm2 g/cm2 
o<E < 10 0.0000 0.0000 0.0000 0.0000 0.0014 0.0000 0.0000 
10<E<20 0.0002 0.0001 0.0001 0.0002 I -0.0005 0.0002 0.0001 
20<E<30 100.9200 0.0026 0.0047 I 0.00381 0.0034 0.0034 0.0027 
30<E<40 62.3110 34.7420 0.0120 I 0.0113 0.0106 -0.0173 0.0077 
40<E<SO 182.3200 87.5770 27.0920 0.0228 0.0203 0.0449 0.0152 
SO<E<60 60.9840 I 74.8840 76.4250 8.3877 0.0465 0.0286 0.0234 
60<E<70 37.l310 38.5120 39.8540 47.8070 10.1310 0.0863 0.0304 
70<E<SO 12.8190 12.6720 13.0140 13.6770 18.2850 1.1767 0.0184 
SO<E<90 18.6730 17.9800 17.7440 18.4560 20.3720 17.4170 9.6162 
90<E<I00 6.9533 6.4465 6.2387 6.0497 6.0333 6.7103 0.0740 
100 < E < 110 5.5312 5.3095 5.1321 4.7738 4.6362 4.6807 0.5870 
110 < E < 120 4.6311 4.2063 3.9976 3.8464 3.6717 3.5148 2.2985 
120 < E < 140 7.0226 6.5373 6.1535 5.6388 5.2939 4.9245 4.8909 
140 < E < 160 2.3553 2.2428 2.1455 2.0033 1.9085 1.7806 1.4574 
160 < E< ISO 1.720t 1.6330 1.5589 1.4607 1.4151 1.3593 1.1201 
ISO <E< 200 2.217 2.1095 2.0100 1.8458 1.7350 1.6424 1.4677 
Sum 505.5901 294.8546 201.3821 113.9843 73.5633 43.3524 21.6096 
Table 6. Eye absorbed dose (cOy) per energy range per aluminum density through 85 
/gJcm2 
I Eye dose (cGy) 
Aluminum 
Densities 
Energy range 
(MeV) 
i 
20 g/cm2 
25 
g/cm2 
35 
g/cm2 
50 
g/cm2 
65 
g/cm2 
85 
g/cm2 
O<E < 10 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
10<E<20 0.0002 0.0001 0.0001 0.0000 0.0000 0.0000 I 
120<E<30 0.0022 0.0017 0.0011 0.0006 0.0004 0.0002 
30<E<40 0.0063 0.0051 0.0035 0.0019 0.0011 0.0005 
40<E<SO 0.0124 0.0103 0.0069 0.0039 022 0.0010 
SO<E<60 0.0195 0.0161 0.0111 0.0063 O.OO'~n 0.0017 
60 <E<70 0.0254 0.0212 0.0149 0.0087 0.0051 0.0025 
70 < E<SO 0.0152 0.0128 0.0091 0.0055 0.0033 0.0016 
SO<E<90 0.0379 0.0304 0.0221 0.0137 0.0084 0.0044 
90<E<100 0.0740 0.0182 0.0130 0.0082 0.0052 0.0028 
100 < E < 110 0.5870 0.0350 0.0141 0.0092 0.0059 0.0033 
110 < E < 120 2.2985 0.2118 0.0157 0.0101 0.0066 0.0037 
120 < E < 140 4.8909 2.9237 0.1241 0.0228 0.0152 0.0089 
140 < E < 160 1.4574 1.4704 0.4524 0.0144 0.0098 0.0059 
160<E< ISO 1.1201 1.0410 0.8658 0.0346 0.0243 0.0156 
ISO < E < 200 1.4677 1.3653 1.2072 0.4476 0.3473 0.2528 
Sum 12.0146 7.1632 2.7608 0.5874 0.4385 0.3050 
18 
Table 7. Eye absorbed dose contribution percentage per energy range per aluminum 
d 't thr h 15 / 2enslry oug. gJcm 
Eye Dose 
percentaee Aluminum Densities 
Energy range 
(MeV) 1 g/cm2 2 g/cm2 
3 
J!/cm2 
5 
J!/cm2 
7 
J!/cm2 
10 
J!/cm2 
15 
J!/cm2 
o<E < 10 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
10<E<20 0.0% 0.0% 0.0% 0.0% 
I 
0.0% 0.0% 0.0% 
20<E<30 20.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
30<E<40 12.3% 11.8% 0.0% 0.0% 0.0% I 0.0% 0.0% 
~<E<SO 36.1% 29.7% 13.5% 0.0% 0.0% 0.1% 0.1% 
<E<60 12.1% 25.4% 38.0% 7.4% 0.1% 0.1% 0.1% 
60 <E<70 7.3% 13.1% 19.8% 41.9% 13.8% 0.2% 0.1% 
70<E<SO 2.5% 4.3% 6.5% 12.0% 24.9% 2.7% 0.1% 
SO<E<90 3.7% 6.1% 8.8% 16.2% 27.7% 40.2% 44.5% 
90 <E< 100 1.4% 2.2% 3.1% 5.3% 8.2% I 15.5% 0.3% 
100 < E < 110 1.1% 1.8% 2.5% 4.2% 6.3% 10.8% 2.7% 
110 < E < 120 0.9% 1.4% 2.0% 3.4% 5.0% 8.1% 10.6% 
120 < E < 140 I 1.4% 2.2% 3.1% 4.9% 7.2% I 11.4% 22.6% 
140 < E< 160 0.5% 0.8% 1.1% 1.8% 2.6% 4.1% 6.7% 
160 <E < lS0 0.3% 0.6% O.8~ l~ 1.9% 1.6% 2.4% 3.1% 5.2% lS0 < E < 200 0.4% 0.7% 1.0 3.8% 6.8% 
Table 8. Eye absorbed dose contribution percentage per energy range per aluminum 
d . thr h 85 / 2enslty ougl gJcm 
Eye dose Aluminum 

percenta2e 
 Densities 

25 
 .35 50 8565Energy range 
(MeV) 20 g/cm2 g/cm2 g/cm2 g/cm2 g/cm2 g/cm2 

0< E < 10 
 0.0% 0.0% 0.0% 
10 <E< 20 
0.0% 0.0% 0.0% 
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% I 
0.0% 0.0% 0.0% 0.1% 0.1% 
30 <E<40 
0.1%20<E<30 
0.1% 0.1%0.1% 0.3% 0.2% 0.2% 
40<E<SO 0.1% 0.1% 0.7% 0.5% 0.3% 
SO<E<60 
0.3% 
0.2% 0.4% 0.5% 
60<E<70 
0.2% 1.1% 0.8% 
0.2% 1.2% 0.8% 
70 <E< SO 
0.3% 0.5% 1.5% 
0.1% 0.2% 0.5% 
SO<E<90 
0.3% 0.9% 0.8% 
0.4% 0.8% 1.4% 
90< E< 100 
0.3% 2.3% 1.9% 
0.6% 0.3% 0.5% 1.4% 1.2% 0.9% I 
1.1% !4.9% 0.5% 1.6% 1.3%0.5%100 < E < 110 
1.2% 
120 < E < 140 
19.1% 3.0% 0.6% 1.7% 1.5%110 < E < 120 
2.9% I40.7% 40.8% 3.9%4.5% 3.5% 
12.1% 20.5% 16.4% 2.5% 2.2% 1.9% 
160 <E< lS0 
140 <E< 160 
14.5%9.3% 31.4% 5.9% 5.5% 5.1% 
[lS0<E<200 12.2% 19.1% 43.7% 76.2% 79.2% 82.9% 
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5.3 BLOOD-FoRMING ORGANS DATA ANALYSIS 
The data shows that blood fonning organs are more susceptible to higher energy 
particles than either the skin or eyes. At low aluminum densities, energies from 80 MeV 
to 120 MeV are important contributors to dose. Again, consistently, the 120 to 140 MeV 
energy range is responsible for most of the absorbed dose for the different aluminum 
densities. Using an aluminum density of 15 g/cm2 greatly reduces the dose received from 
46.3 cGy using 1 g/cm2 to 7.4 cGy. All the energies below 120 MeV become small 
contributors, with the primary dose coming energies between 120 and 160 MeV. 
The ICRP 60 report recommends no more than 500 mSv per year for blood 
forming organs. Table 21 shows that an aluminum density of 3 glcm2 meets this 
requirement, resulting in a dose equivalent of 452.7 mSv. At this aluminum density, the 
there are two peaks in the energy contributions: at 80 < E < 90 MeV, comprising 20.8% 
of the dose equivalent (93.9 mSv) and at 120 < E < 140 MeV, 15.8% of the dose 
equivalent (71.3 nlSv). 
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5.3.1 BLOOD FORMING ORGANS ABSORBED DOSE TABLES 
Table 9. Blood forming organs absorbed dose (cOy) per energy range per aluminum 
d . thr h 15 I ')enslty ougJ g,cm-
BFO dose (cGy) Aluminum Densities 
Energy range (Me V) 
1 
g/cm2 
2 
g/cm2 
3 
g/cm2 
5 
g/cm2 
7 
g/cm2 
10 
g/cm2 
15 
g/cm2 
o<E < 10 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
10<E<20 0.0002 0.0002 0.0001 0.0002 0.0002 0.0001 0.0001 
20 <E< 30 0.1455 0.0024 0.0023 0.0021 0.0018 0.0017 0.0014 
30<E<40 0.0532 -0.0434 0.007 0.0067 0.0062 0.0055 0.0045 
40<E<50 0.5326 0.1436 0.024 0.0141 0.0131 0.0116 0.0095 
50<E<60 3.3653 0.6469 0.235 0.0129 0.0213 0.0191 0.0158 
60<E<70 5.5833 4.5573 2.6329 0.2955 0.0339 0.0257 0.0215 
70 < E < SO 4.7360 3.2265 2.0810 1.0661 0.1488 0.0167 0.0133 
SO<E<90 8.8777 7.8593 6.7059 4.1894 2.1154 0.3457 0.0348 
90<E<100 5.0096 4.0973 3.5231 2.7724 2.0148 0.8919 0.0523 
l00<E<110 4.0777 4.1469 3.9185 2.9787 2.3074 1.4346 0.2512 
110 <E< 120 3.5351 3.2303 3.0843 3.0027 2.5577 1.7755 0.6939 
120 < E < 140 5.8452 5.6420 5.3876 4.8420 4.4201 3.7546 2.4045 
140 <E < 160 1.9094 1.9214 1.9219 1.8728 1.7881 1.6323 1.2911 
160 < E < ISO 1.3302 1.3122 1.3026 1.3050 1.3163 1.2941 1.1516 
IS0<E<200 1.6816 1.6495 1.6204 1.5704 1.5312 1.4963 1.4636 
Sum 46.2851 38.3924 32.3986 23.9311 18.2763 12.7052 7.4091 
BFO dose (cGy) 
Aluminum 
Densities I 
Energy range (MeV) 20 glcm2 
25 
glcm2 
35 
glcm2 
50 
glcm2 
65 
glcm2 
85 
glcm2 
o<E < 10 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
10<E<20 0.0001 0.0000 0.0000 0.0000 0.0000 0.0000 
20 <E< 30 0.0011 0.0009 0.0006 0.0003 0.0002 0.0001 
30<E<40 0.0037 0.0030 0.0020 0.0011 0.0006 0.0002 
40 <E< 50 0.0079 0.0065 0.0044 0.0024 0.0013 0.0006 
50<E<60 0.0130 0.0108 0.0074 0.0042 0.0023 0.0010 
60 <E<70 0.0180 0.0151 0.0105 0.0062 0.0034 0.0016 
70<E<SO 0.0112 0.0095 0.0068 0.0041 0.0023 0.0011 
SO<E<90 0.0279 0.0238 0.0173 0.0108 0.0064 0.0032 
90 <E< 100 0.0171 0.0143 0.0106 0.0068 0.0041 0.0022 
l00<E<110 0.0264 0.0160 0.0119 0.0078 0.0048 0.0026 
110 < E < 120 0.0968 0.0212 0.0131 0.0087 0.0055 0.0030 
120 < E < 140 1.0557 0.2789 0.0332 0.0202 0.0130 0.0074 
140 < E< 160 0.9257 0.4989 0.0473 0.0114 0.0075 0.0044 
160<E< ISO 0.9321 0.6789 0.1590 0.0136 0.0092 0.0056 
IS0<E<200 1.3852 1.2254 0.7115 0.1034 0.0784 0.0562 
Sum 4.5219 2.8032 1.0357 0.2012 0.1390 0.0891 
Table 10. Blood forming organs absorbed dose (cOy) per energy range per aluminum 
d . th h 85 / 2enslty rougJ g,cm 
. 
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Table 11. Blood forming organs absorbed dose contribution percentage per energy range 
I' d . th h 15 / 2per a Umll1Um enslty rougj gJcm 
BFOdose 
percenta2e Aluminum Densities 
Energy range 1 2 3 5 7 10 15 
(MeV) g/cm2 g/cm2 g/cm2 g/cm2 g/cm2 g/cm2 g/cm2 
0< E < 10 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
10<E<20 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
20<E<30 0.3% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
30<E<40 0.1% 0.1% 0.0% 0.0% 0.0% 0.0% 0.1% 
40 <E< 50 1.2% 0.4% 0.1% 0.1% 0.1% 0.1% 0.1% 
50<E<60 7.3% 1.7% 0.7% 0.1% 0.1% 0.1% 0.2% 
60<E<70 12.1% 11.9% 8.1% 1.2% 0.2% 0.2% 0.3% 
70<E<SO 10.2% 8.4% 6.4% 4.5% 0.8% 0.1% I 0.2% 
SO<E<90 19.2% 20.5% 20.7% 17.5% 11.6% 2.7% 0.5% 
90 <E < 100 10.8% 10.7% 10.9% 11.6% 11.0% 7.0% 0.7% 
100 <E < 110 8.8% 10.8% 12.1% 12.4% 12.6% 11.3% 3.4% 
110<E<120 7.6% 8.4% 9.5% 12.5% 14.0% 14.0% 9.4% 
120<E < 140 12.6% 14.7% 16.6% 20.2% 24.2% 29.6% 32.5% 
140 <E< 160 4.1% 5.0% 5.9% 7.8% 9.8% 12.8% 17.4% 
160 <E < ISO 2.9% 3.4% 4.0% 5.5% 7.2% 10.2% 15.5% 
i IS0<E <200 3.6% 4.3% 5.0% 6.6% 8.4% 11.8% 19.8% 
I' d'per a umlnum enslty th h 85rougl / 2gJcm 
BFOdose 
percentage 
Aluminum 
Densities 
Energy range 
(MeV) 20 g/cm2 
25 
g/cm2 
35 
g/cm2 
50 
g/cm2 
65 
g/cm2 
85 
I 
g/cm2 
o<E < 10 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% : 
10 <E <20 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% i 
20<E<30 0.0% 0.0% 0.1% 0.2% 0.1% 0.1% 
30<E<40 0.1% 0.1% 0.2% 0.6% 0.4% 0.3% 
40<E<SO 0.2% 0.2% 0.4% 1.2% 0.9% 0.6% i 
50 <E<60 0.3% 0.4% 0.7% 2.1% 1.6% 1.1% I 
60<E<70 0.4% 0.5% 1.0% 3.1% 2.5% 1.8% I 
70<E<SO 0.2% 0.3% 0.7% 2.0% 1.7% 1.3% 
SO<E<90 0.6% 0.8% 1.7% 5.4% 4.6% 3.6% 
90<E< 100 0.4% 0.5% 1.0% 3.4% 3.0% 2.4% 
100 < E < 110 0.6% 0.6% 1.1% 3.9% 3.5% 2.9% i 
110 < E < 120 2.1% 0.8% 1.3% 4.3% 4.0% 3.4% 
120 < E < 140 23.3% 10.0% 3.2% 10.0% 9.4% 8.3% 
140 < E < 160 20.5% 17.8% 4.6% 5.7% 5.4% 4.9% i 
160 < E < ISO 20.6% 24.2% 15.3% 6.8% 6.6% 6.3% 
ISO < E< 200 30.6% 43.7% 68.7% 51.4% 56.4% 63.1% 
Table 12. Blood forming organs absorbed dose contribution percentage per energy range 
I 
I 
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6.0 CONCLUDING REMARKS 
Using BRYNTRN and MATLAB, organ doses and dose equivalents were able to 
be extracted into the useful form as a function of particle energy and aluminum thickness. 
These are presented in tabular form and are also graphically depicted in the appendix. 
The data shows that the minimum aluminum shield thickness should be 25 g/cm2 to meet 
the ICRP 60 dose limits. This value is from the eye/ocular lens data, the most 
conservative of the three organs in which calculations were run. Also, it was noticed that 
the differing aluminum depths had different primary energy contributors- as aluminum 
depth increased, the primary contributors increased in energy. Also, the energies 120 to 
140 MeV are highly active among all the organs in this research and should be carefully 
dealt with in future research. This data is indicative of a worst-case scenario modeled 
using the October 19, 1989 data. It can be used as an upper bound for doses received by 
space crew personnel. 
For future research, probability models that can accurately predict SPEs need to 
be developed. Also, dose limits need to be developed for missions outside the Earth's 
magnetosphere. This research utilized the ICRP 60 occupational dose limits, which can 
hardly be extrapolated to the dynamics of deep-space radiation protection. The minimal 
aluminulll thickness this research determines to be needed is likely to be too heavy and 
costly. Lastly, the duration of SPEs cannot be reliably predicted4• This has a huge impact 
on the dose quantities, as longer-term events increase dose. New shielding technologies 
that mitigate the energies shown to be prevalent in this research should be researched. 
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8.0 ApPENDIX 
8.1 DOSE EQUIVALENT TABLES: SKIN, EYE, BLOOD FORMING ORGANS 
Table 13. Skin dose equivalent (cSv) per energy range per aluminum density through 15 
/ 2gJcm 
Skin dose eg. (cSv) Aluminum Densities 
Energy range 
. (MeV) 191cm2 2wcm2 3 g/cm2 5 g/cm2 7 g/cm2 10 g/cm2 15 g/cm2 
0< E < 10 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
10<E<20 0.0040 0.0046 0.0039 0.0049 0.0034 0.0023 0.0024 
20<E<30 902.8600 0.0531 0.0489 0.0456 0.0432 0.0379 0.0304 
30<E<40 213.2500 316.2500 0.1079 0.0979 0.0903 0.0811 0.0661 
40< E< 50 136.1300 154.0500 195.9000 0.1573 0.1466 0.1294 0.1073 
50<E<60 69.1250 65.7550 85.1880 63.5150 0.3275 0.1758 0.1454 
60 <E <70 35.5130 40.2190 42.3970 65.9970 45.5530 0.5308 0.1740 
70<E<SO 14.5830 13.7050 13.0820 14.9350 21.6590 5.9106 0.0992 
SO<E<90 22.2290 20.4590 20.1770 19.8890 21.2480 31.1200 14.7300 
90<E< 100 9.9989 8.4502 7.6250 7.0195 6.8912 7.1888 0.2761 
! 100<E<110 7.7841 7.4141 7.0613 6.1161 5.5242 5.3281 1.6233 
110 < E< 120 6.2572 5.6606 5.3233 5.2454 4.8893 4.2687 4.3548 
120 < E < 140 9.3579 8.6590 8.0500 7.2979 6.9708 6.5630 5.9368 
140 < E < 160 3.2405 3.0772· 2.9202 2.6651 2.5002 2.3150 1.9053 
160 < E < ISO 2.4946 2.3594 2.2306 2.0341 1.9255 1.8215 1.5074 
lS0<E<200 3.3568 3.2133 3.0640 2.7936 2.5856 2.3899 2.0145 
Sum 1436.1840 649.3295 393.1791 197.8134 120.3578 67.8629 32.9730 
Table 14. Skin dose equivalent (cSv) per energy range per aluminum density through 85 
/gJcm2 
Skin dose eq. (cSv) Aluminum Densities I 
20 35 I 
Ener2yran~e(MeV) wcm 2 25 wcm 2 wcm 2 50wcm2 65 wcm 2 S5 wcm 2 
o<E < 10 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
10<E<20 0.0020 0.0015 0.0010 0.0005 0.0005 0.0002 
20<E<30 0.0248 0.0202 0.0133 0.0072 0.0058 0.0028 : 
30<E<40 0.0542 0.0446 0.0299 0.0165 0.0127 0.0063 
40<E<50 0.0883 0.0726 0.0493 0.0276 0.0208 0.0103 
50<E<60 0.1208 0.1002 0.0688 0.0393 0.0293 0.0147 
60<E<70 0.1453 0.1214 0.0847 0.0495 0.0369 0.0189 
70 <E< SO 0.0814 0.0687 0.0486 0.0291 0.0217 0.0113 
SO <E<90 0.1912 0.1549 0.1116 0.0685 0.0513 0.0276 
90 <E< 100 0.2761 0.0877 0.0627 0.0396 0.0298 0.0165 
100 < E < 110 1.6233 0.1369 0.0667 0.0428 0.0324 0.0182 j 
110 < E < 120 4.3548 0.5750 0.0714 0.0460 0.0349 0.0200 . 
120<E< 140 5.9368 4.7184 0.3432 0.1002 0.0766 0.0450 
140 < E < 160 1.9053 ·1.7709 0.8463 0.0573 0.0439 0.0264 
160<E<lS0 1.5074 1.3739 1.2314 0.0951 0.0730 0.0461 
ISO < E < 200 2.0145 1.8638 1.5922 0.7295 0.5968 0.4313 
Sum 18.3261 11.1103 4.6212 1.3484 1.0661 0.6955 
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Table 15. Skin dose equivalent (cSv) contribution percentage per energy range per 
I' d' thr h 15 / 2a UIll1num enslty ougJ gJcm 
Skin dose eq. Aluminum 
_percentaae Densities 
Energy range 
(MeV) 1 g/cm2 2 g/cm2 3 glcm2 5 glcm2 7 glcm2 10 fJlcm2 15 g/cm2 
O<E < 10 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
10 <E<20 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
20<E< 30 62.9% 0.0% 0.0% 0.0% 0.0% 0.1% 0.1% i 
30<E<40 14.8% 48.7% 0.0% 0.0% 0.1% 0.1% 0.2% i 
40<E<50 9.5% 23.7% 49.8% 0.1% 0.1% 0.2% 0.3% 
50<E<60 4.8% 10.1% 21.7% 32.1% 0.3% 0.3% 0.4% 
60<E<70 2.5% 6.2% 10.8% 33.4% 37.8% 0.8% 0.5% 
70<E<SO 1.0% 2.1% 3.3% 7.6% 18.0% 8.7% 0.3% 
SO<E<90 1.5% 3.2% 5.1% 10.1% 17.7% 45.9% 44.7% 
90 < E < 100 0.7% 1.3% 1.9% 3.5% 5.7% 10.6% 0.8% 
100 < E < 110 0.5% 1.1% 1.8% 3.1% 4.6% 7.9% 4.9% i 
110 < E < 120 0.4% 0.9% 1.4% 2.7% 4.1% 6.3% 13.2% 
120 < E < 140 0.7% 1.3% 2.0% 3.7% 5.8% 9.7% 18.0% 
140 < E < 160 0.2% 0.5% 0.7% 1.3% 2.1% 3.4% 5.8% i 
160 < E < ISO 0.2% 0.4% 0.6% 1.0% 1.6% 2.7% 4.6% 
ISO < E <200 0.2% 0.5% 0.8% 1.4% 2.1% 3.5% 6.1% 
Table 16. Skin dose equivalent (cSv) contribution percentage per energy range per 
I' d' h h 85 / 2a UIll1num enslty t roug] gJcm 
Skin dose eq. 
percentage 
Aluminum 
Densities 
Energy range 
(MeV) 20 g/cm2 25 g/cm2 35 g/cm2 50 g/cm2 65 g/cm2 S5 g/cm2 
O<E < 10 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
10<E<20 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
20<E<30 0.1% 0.2% 0.3% 0.5% 0.5% 0.4% 
30<E<40 0.3% 0.4% 0.6% 1.2% 1.2% 0.9% 
40<E<50 0.5% 0.7% 1.1% 2.0% 1.9% 1.5% 
50<E<60 0.7% 0.9% 1.5% 2.9% 2.7% 2.1% 
60 < E < 70 0.8% 1.1% 1.8% 3.7% 3.5% 2.7% 
70<E<SO 0.4% 0.6% 1.1% 2.2% 2.0% 1.6% 
SO<E<90 1.0% 1.4% 2.4% 5.1% 4.8% 4.0% 
90<E<100 1.5% 0.8% 1.4% 2.9% 2.8% 2.4% 
100<E<110 8.9% 1.2% 1.4% 3.2% 3.0% 2.6% 
110< E< 120 23.8% 5.2% 1.5% 3.4% 3.3% 2.9% 
120 < E < 140 32.4% 42.5% 7.4% 7.4% 7.2% 6.5% 
140 <E< 160 10.4% 15.9% 18.3% 4.2% 4.1% 3.8% 
160 < E < ISO 8.2% 12.4% 26.6% 7.1% 6.8% 6.6% 
lS0<E<200 11.0% 16.8% 34.5% 54.1% 56.0% 62.0% 
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Table 17. Eye dose equivalent (cSv) per energy range per aluminum density through 15 
/ 2gJcm 
Aluminum I 
Eye dose eg. (cSv) Densities 
Energy range 
(MeV) 1 g/cm2 2 g/cm2 3 g/cm2 5 g/cm2 7 g/cm2 10 g/cm2 15 g/cm2 
O<E< 10 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
10<E<20 0.0017 I 0.0020 0.0016 0.0031 0.0020 0.0015 0.0012 
20<E<30 272.4700 0.0472 0.0431 -0.1967 0.0382 0.0335 0.0275 
30<E<40 102.0600 95.5100 0.1141 0.3400 0.0952 0.0848 0.0691 
40<E<50 280.2900 159.9300 59.2460 0.1722 0.1594 0.1416 0.1172 
50 < E < 60 65.7890 76.0230 122.9000 20.3620 0.2592 0.1957 0.1617 
60 <E< 70 43.1890 48.60QQ .... 45.1780 71.7230 20.2840 0.3464 0.1936 
70<E<SO 15.5620 15.2140 15.3010 16.2260 27.7330 2.5227 0.1085 
SO<E<90 23.3790 22.3070 21.9000 22.5170 24.1480 26.4740 13.5100 
90<E<100 9.0868 8.3014 7.9474 7.6512 7.4619 8.1950 0.2057 
100 < E < 110 7.1798 6.8971 6.6995 6.1758 5.9285 5.8147 1.0642 
110 < E < 120 6.2165 5.5957 5.2575 5.0451 4.8090 4.5272 3.5474 
120 < E< 140 9.5118 8.8657 8.3365 7.6051 7.1074 6.5632 6.4064 
140 < E < 160 3.2624 3.1048 2.9664 2.7599 2.6219 2.4448 1.9470 
160<E< ISO 2.4546 2.3267 2.2144 2.0584 1.9818 1.8962 1.5436 I 
ISO < E < 200 3.2699 3.1144 2.9667 I 2.7176 2.5431 2.38~H= 2.0940 
Sum 843.7225 455.8390 301.0722 165.1597 105.1726 61.6308 30.9971 
Table 18. Eye dose equivalent (cSv) per energy range per aluminum density through 85 

/ 2gJcm 
Aluminum 
Eye dose eq. (cSv) Densities 
Energy range 
(MeV) 20 g/cm2 25 g/cm2 35 g/cm2 50 g/cm2 65 g/cm2 S5 g/cm2 
0< E < 10 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
10<E<20 0.0011 0.0008 0.0005 0.0003 0.0002 0.0001 
20<E< 30 0.0224 0.0183 0.0120 0.0065 0.0040 0.0018 
30 < E < 40 0.0566 0.0465 i 0.0313 0.0172 0.0103 0.0046 
40<E<50 0.0963 0.0793 I 0.0538 0.0301 0.0178 0.0081 
50<E<60 0.1343 0.1112 0.0764 0.0435 0.0258 0.0119 
60 <E<70 0.1616 0.1350 0.0942 0.0550 0.0330 0.0156 
70 < E < SO 0.0905 0.0762 0.0539 0.0322 0.0196 0.0095 
SO<E<90 0.2059 0.1710 0.1231 0.0755 0.0469 0.0235 
90<E< 100 0.2057 0.0952 0.0689 0.0434 0.0274 0.0143 
100 < E < 110 1.0642 0.1262 0.0730 0.0468 0.0300 0.0159 
110 < E < 120 3.5474 0.4169 0.0775 0.0501 0.0326 0.0177 
120 < E < 140 6.4064 4.2681 0.3034 0.1088 0.0720 0.0403 
140<E< 160 1.9470 1.9131 0.7193 0.0608 0.0409 0.0236 
160 < E < ISO 1.5436 1.4081 1.2174 0.0913 0.0634 0.0388 
ISO < E < 200 2.0940 1.9333 1.6610 0.6932 0.5369 0.3836 
Sum 17.5769 10.7991 4.5659 1.3547 0.9608 0.6092 
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Table 19. Eye dose equivalent (cSv) contribution percentage per energy range per 
I' d' thr h 15 I 2a umInum ensIty ougJ gJcm 
Eye dose eq. Aluminum 
percentage Densities 
Energy range 
(MeV) 1 glcm2 2 glcm2 3 glcm2 5 glcm2 7 glcm2 10 glcm2 15 glcm2 
0< E < 10 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
10<E<20 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
20<E<30 32.3% 0.0% I 0.0% -0.1% 0.0% 0.1% 0.1% 
30<E<40 12.1% 21.0% 0.0% 0.2% 0.1% 0.1% 0.2% 
40<E<50 33.2% 35.1% 19.7% 0.1% 0.2% 0.2% 0.4% 
50<E<60 7.8% 16.7% 40.8% 12.30/0 0.2% 0.3% 0.5% 
60 < E< 70 5.1% 10.7% 15.0% 43.4% 19.3% 0.6~ 0.6% 
70<E<SO 1.8% 3.3% 5.1% 9.8% 26.4% 4.1% 0.4% J 
SO<E<90 2.8% 4.9% 7.3% 13.6% 23.0% 43.0% 43.6% 
90<E< 100 1.1~ 1.8% 2.6% 4.6% 7.1% 13.3% 0.7% i 
100 < E < 110 -0.9% 1.5% 2.2% 3.7% 5.6% 9.4% 3.4% I 
110 < E < 120 0.7% 1.2% 1.7% 3. 4.6% 7.3% 11.4% 
120 < E < 140 1.1% 1.9% 2~ 4.6% 6.8% 10.6% 20.7% ! 140<E< 160 0.4% 0.7% 1. I 1.7% 2.5% 4.0% 6.3% 
160 < E < ISO 0.3% 0.5% 0.7% 1.2% 1.9% 3.1% I 5.0% 
lS0<E<200 0.4% 0.7% 1.0% 1.6% 2.4% 3.9% 6.8% 
Eye dose eq. 
percentage 
Aluminum 
Densities 
! 
Energy range 
(MeV) 20 f!/cm2 25 f!/cm2 35 g/cm2 50 f!/cm2 65 f!/cm2 S5 f!/cm2 
0< E < 10 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
110<E<20 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
20<E<30 0.1% 0.2% 0.3% 0.5% 0.4% 0.3% 
30<E<40 0.3% 0.4% 0.7% 1.3% 1.1% 0.8% 
40<E<50 0.5% 0.7% 1.2% 2.2% 1.9% 1.3% 
50<E<60 0.8% 1.0% 1.7% 3.2% 2.7% 1.9% 
60<E<70 0.9% 1.2% 2.1% 4.1% 3.4% 2.6% 
70<E< SO 0.5% 0.7% 1.2% I 2.4% 2.0% 1.6% 
SO<E<90 1.2% 1.6~ 2.7% 5.6% 4.9% 3.9% 
90<E< 100 1.2% 0.9% 1.5% 3.2% 2.9% 2.3% 
100 < E < 110 6.1% 1.2% 1.6% 3.5% 3.1% 2.6% 
110<E<120 20.2% 3.9% 1.7% 3.7% 3.4% 2.9% 
120<E< 140 36.4% 39.5% 6.6% 8.0% 7.5% 6.6% 
140 < E < 160 11.1% 17.7% I 15.8% 4.5% 4.3% 3.9% 
160<E< ISO 8.8% I 13.0% 26.7% 6.7% 6.6% 6.4% 
180 < E < 200 11.9% 17.9% 36.4% 51.2% 55.9% 63.0% 
Table 20. Eye dose equivalent (cSv) contribution percentage per energy range per 
I' d' thr h 85 I 2a umInum ensIty ougJ gJcm 
i 
. 
I 
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Table 21. Blood fonning organs dose equivalent (cSv) per energy range per aluminum 
d . thr h 15 I 2enslty ougJ gJcm 
BFOdoseeq. Aluminum 
(cSv) Densities 
Energy range 
(MeV) 1 g/cm2 2 g/cm2 3 g/cm2 5 g/cm2 7 g/cm2 10 g/cm2 15 g/cm2 
0< E< 10 0.0000 0.0000 0.0000 0.0000 -0.5753 0.0000 0.0000 
10 < E < 20 0.0008 0.0007 0.0006 0.0007 0.0005 0.0005 0.0004 
20 < E < 30 0.3757 0.0232 0.0224 0.0206 0.0190 0.0167 
30< E <40 0.1119 -0.0756 
-
~~ 0.0467 0.0383 40<E<50 0.9425 0.4688 0.0837 0.0690 
50< E<60 6.8438 1.2389 0.1223 0.1357 0.1212 0.1005 
60<E<70 7.5527 7.1643 0.6727 0.1780 0.1500 0.1253 
70< E< 80 6.6912 4.9653 2.9103 1.8856 0.3331 0.0872 0.0722 
80<E<90 11.8730 10.5540 9.3924 6.0556 3.3542 0.7093 0.1687 
90<E<100 6.8754 5.5716 4.6941 3.7634 2.8573 1.3998 0.1472 
~llU 5.1015 5.3523 5.2339 4.0228 3.1323 2.0546 0.4554 
< 120 4.6945 4.2156 3.9530 3.9203 3.4436 2.4293 1.0591 
120<R< 140 7.6842 7.4474 7.1318 6.3935 5.8209 5.0016 3.3212 
140 < E < 160 2.5360 2.5501 2.5537 2.4942 2.3792 2.1810 1.7273 
160 < E < 180 1.8428 1.8082 1.7843 1.7684 1.7740 1.7411 1.5530 
180 < E < 200 2.4243 2.3745 2.3290 2.2481 2.1800 2.1076 2.0309 I 
Sum 65.5503 53.6593 45.2652 33.5267 25.1792 18.1304 10.8820 
Table 22. Blood fonning organs dose equivalent (cSv) per energy range per aluminum 
d . thr h 85 I 2enslty ougJ ~cm 
Aluminum 
BFO dose eq. (cSv) Densities 
20 
Energy range (MeV) g/cm2 25 g/cm2 35 g/cm2 50 g/cm2 65 g/cm2 85 g/cm2 
O<E< 10 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
10<E<20 0.0003 0.0002 0.0002 0.0001 0.0000 0.0000 
20<E<30 0.0111 0.0090 0.0060 0.0032 0.0017 0.0007 
30<E<40 0.0314 0.0258 0.0173 0.0096 0.0050 0.0021 
40<E<50 0.0568 0.0468 0.0317 0.0177 0.0094 0.0040 
50<E<60 0.0833 0.0690 0.0474 0.0270 0.0145 0.0064 
60<E<70 0.1048 0.0875 0.0612 0.0358 0.0196 0.0089 
70 < E < 80 0.0608 0.0512 0.0363 0.0218 0.0122 0.0057 
80 < E < 90 0.1403 0.1192 0.0862 0°'°15090<E< 100 0.0798 0.0678 0.0499 0.0095 
100 < E < 110 0.0973 0.0729 0.0540 O. 0.0110 
110 < E < 120 0.2078 0.0831 0.0580 0.0381. 0.0125 
120 < E < 140 1.5866 0.5129 0.1314 0.0848 ~O,0294 
140 < E < 160 1.2728 0.7316 0.1120 0.0463 0.0168 
160<E< 180 1.2619 0.9415 0.2653 0.0503 0.0329 0.0192 
180<E<200 1.9078 1.6873 1.0185 0.2044 0.1487 0.1013 
Sum 6.9026 4.5057 1.9754 0.6587 0.4209 0.2425 
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Table 23. Blood fonning organs dose equivalent (cSv) contribution percentage per energy 
ran e er aluminum densit throu h 15 /cm2 
, BFO dose eq. Aluminum 
ercenta e Densities 
Energy range 
(MeV) 1 S cm2 
O<E< 10 0.0% 0.0% 0.0% 0.0% -2.3% 0.0% 
10<E<20 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
20<E<30 0.6% 0.0% 0.0% 0.1% 0.1% 0.1% 0.1% 
30<E<40 0.2% -0.1% 0.1% 0.2% 0.2% 0.3% 0.4% 
40<E<SO 1.5% 0.9% 0.1% 0.3% 0.4% 0.5% 0.6% 
SO<E<60 10.6% 2.3% 1.2% 0.4% 0.5% 0.7% 0.9% 
60<E<70 11.7% 13.4% 10.2% 2.0% 0.7% 0.8% 1.2% 
70<E< SO 9.3% 6.4% 5.6% 
SO<E< 90 19.7% 20.8% 18.1% 
90<E< 100 10.4% 10.4% 11.2% 
100 <E < 110 10.0% 11.6% 12.0% 12. 
110 <E < 120 7.9% 8.7% 11.7% 9.7% 
120 < E < 140 13.9% 30.5% 
140<E< 160 4.8% 15.9% 
160<E< ISO 3.4% 7. 14.3% 
lS0<E<200 4.4% 18.7% 
Table 24. Blood fonning organs dose equivalent (cSv) contribution percentage per energy 
ran e er aluminum densit throu h 85 cm2 
BFOdoseeq. Aluminum 
Densities 
o<E < 10 
10<E<20 0.0% 
20<E<30 0.5% 
! 30<E<40 0.5% 1.5% 
140 <E< SO 0.8% 1.0% 1.6% 2.7% 
SO<E<60 1.2% 1.5% 2.4% 4.1% 3.4% 
60<E<70 1.5% 1.9% 3.1% 5.4% 4.7% 3.7% 
70<E<SO 0.9% 1.1% 1.8% 3.3% 2.9% 2.4% 
SO<E<90 2.0% 2.6% 4.4% 8.1% 7.3% 6.2% 
90<E<100 1.2% 1.5% 2.5% 4.8% 4.5% 3.9% 
l00<E<110 1.4% 1.6% 2.7% 5.3% 5.0% 4.5% 
110 < E < 120 3.0% 1.8% 2.9% 5.8% 5.6% 5.2% 
120<E< 140 23.0% 11.4% 6.7% 12.9% 12.7 
140 < E < 160 18.4% 16.2% 5.7% 7.0% 7.0 
160<E< ISO 18.3% 20.9% 13.4% 7.6% 7.9% 
lS0<E<200 27.6% 37.4% 51.6% 31.0% 41.8% 
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8.2 QUALITY FACTOR TABLES: SKIN, EYE, BLOOD FORMING ORGANS 
T bi 25 Sk· gJcm2 a e In qua lty r factors per energy range per a1ullllnum denslt v througJh 15 / 
Skin quality 
factor 
Energy range 
(MeV) 
0< E < 10 
10 < E < 20 
20<E< 30 
30 < E < 40 
40<E < 50 
50 < E < 60 
60 < E < 70 
70 < E < 80 
80 < E < 90 
90<E< 100 
100 < E < 110 
110 < E < 120 
120 < E < 140 
140 < E < 160 
160 < E < 180 
180 < E < 200 
Aluminum 
Densities 
1 g/cm2 2 g/cm2 3 g/cm2 
1.8558 1.6756 1.6011 
1.8558 1.6756 1.6011 
1.536 1.6764 1.601 
1.2443 1.4515 1.6007 
1.2658 1.2336 1.4349 
1.2792 1.271 1.2739 
1.3205 1.3186 1.3019 
1.3484 1.3431 1.3369 
1.3693 1.3682 1.3656 
1.388 1.3916 1.3906 
1.4049 1.408 1.4071 
1.4281 1.4311 1.4293 
1.4647 1.4693 1.4694 
1.5063 1.5116 1.5121 
1.5369 1.5428. 1.544 
1.5847 1.5909 1.5927 
5 g/cm2 
1.5337 
1.5334 
1.5332 
1.5328 
1.5319 
1.4204 
1.3103 
1.3231 
1.356 
1.3864 
1.4035 
1.4236 
1.4643 
1.5091 
1.5423 
1.5927 
7 g/cm2 
1.5038 
1.5038 
1.5035 
1.5028 
1.5016 
1.4995 
1.4033 
1.3118 
1.3426 
1.3804 
1.4007 
1.4198 
1.4583 
1.5038 
1.5382 
1.5908 
10 g/cm2 
1.4876 
1.4876 
1.4872 
1.4862 
1.4843 
1.4817 
1.4758 
1.4516 
1.3909 
1.3649 
1.392 
1.4148 
1.4531 
1.4968 
1.5313 
1.5859 
15 g/cm2 
1.493 
1.493 
1.4924 
1.4906 
1.4875 
1.4831 
1.4777 
1.4731 
1.4741 
1.4725 
1.4548 
1.4212 
1.4295 
1.474 
1.5093 
1.57 
T bi 26 Sk· In qua lty actors per energy range per a1umlnum d hr h 85 g/cm2 a e r f ensltv t ougJ 
Skin quality 
factor 
Energy range 
(MeV) 
o<E < 10 
10<E<20 
20<E< 30 
30<E< 40 
40 < E < 50 
50<E< 60 
60< E<70 
70 < E < 80 
80 < E < 90 
90<E< 100 
100 < E < 110 
110 < E < 120 
120 < E < 140 
140 < E < 160 
160 < E < 180 
180 < E < 200 
Aluminum 
Densities 
20 g/cm2 25 g/cm2 
1.5183 1.556 
1.5182 1.5559 
1.5174 1.5548 
1.5149 1.5515 
1.5104 1.5457 
1.5041 1.5373 
1.4962 1.5268 
1.4896 1.518 
1.482 1.5078 
1.4725 1.4969 
1.4548 1.4886 
1.4212 1.4755 
1.4295 1.454 
1.474 1.4603 
1.5093 1.4983 
1.57 1.5607 
35 g/cm2 
1.6572 
1.6571 
1.6555 
1.6507 
1.6421 
1.6296 
1.6137 
1.6002 
1.5843 
1.5672 
1.5547 
1.5415 
1.5183 
1.4905 
1.486 
1.5392 
50 g/cm2 
1.8552 
1.8551 
1.8529 
1.8462 
1.8339 
1.8159 
1.7926 
1.7724 
1.748 
1.7211 
1.701 
1.6793 
1.6438 
1.6064 
1.5799 
1.5606 
65 g/cm2 
1.8719 
1.8717 
1.8695 
1.863 
1.8515 
1.8348 
1.8133 
1.7946 
1.7719 
1.747 
1.7281 
1.7079 
1.6745 
1.6393 
1.6138 
1.5879 
85 g/cm2 
1.7757 
1.7756 
1.7742 
1.77 
1.7626 
1.7516 
1.7373 
1.7247 
1.709 
1.6915 
1.6779 
1.6631 
1.6383 
1.6118 
1.5919 
1.568 
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T bI 27 E ft f ta e ~ye qua ley ac ors per eneq 1;y range per a umlnum d . thenslty hJ5 Iroug. gicm2 
Aluminum 
Eye quality factor Densities 
Energy range 
(MeV) 1 glcm2 2 glcm2 3 glcm2 5 glcm2 7 glcm2 10 glcm2 15 glcm2 
0< E < 10 1.6684 H.5463 1.496 1.4513 1.4335 1.4277 1.4432 
10 <E < 20 1.6684 1.5463 1.496 1.4513 1.4335 1.4277 1.4431 
20<E< 30 1.5405 1.5462 1.4959 1.4511 1.4333 1.4274 1.4426 
30<E<40 1.3922 1.4664 I 1.4956 1.4506 1.4325 1.4263 1.4408 
40<E<50 1.2788 1.2765 1.4422 1.4496 1.4311 1.4242 1.4375 
50 <E<60 1.2179 1.223 1.3052 1.4108 i 1.429 1.4212 1.4326 
60<E<70 1.2753 1.2854 2.7505 1.3214 1.383 1.4169 1.4265 
70<E<SO 1.3114 1.3028 2.794 1.2827 1.3061 1.4046 1.4214 
SO<E<90 1.3423 1.3364 1.331 1.3204 1.3033 1.3531 1.4249 
90<E< 100 1.37 1.3675 1.3643 1.3571 1.3468 1.327 1.4265 
100 < E < 110 1.3885 1.3879 1.3851 1.3792 31 1.3584 1.4135 
110 < E < 120 1.408 1.4089 1.4066 1.4017 .3966 1.3877 1.3888 
120 < E < 140 1.4424 1.4442 1.4435 1.4389 1.4336 1.4275 1.4021 
140 < E < 160 1.4844 1.486 1.4854 1.4813 1.475~ 1.4696 1.4489 
160 < E < ISO 1.5151 1.5177 1.518 1.5157 1.5113 1.5044 1.4847 
IS0<E<200 1.5584 1.5618 1.563 1.5635 1.5624 1.5589 1.5456 
T bI 28 E rt f ta e .. ~ye qua ICY ac ors per enef! 1~y range per a umlnum denslty througj 
Aluminum 
Eye quality factor Densities 
Energy range 
(MeV) 20 g1cm2 25 g1cm2 35 J!/cm2 50 glcm2 65 glcm2 S5 J!/cm2 
o<E < 10 1.4752 1.5182 1.6281 1.8364 1.7591 1.6526 
10<E<20 1.4752 1.5182 1.6281 1.8363 1.759 1.6525 , 
~E<30 1.4744 I 1.5172 1.6267 1.8345 1.7576 1.6517 
<E<40 1.4719 1.5139 1.622 1.828 1.7527 1.6488 
40<E<50 1.4672 1.5078 H.6131 1.8155 1.7434~ 
50<E<60 1.4603 1.4988 .5998 1.7967 1.7294 1.6348 
60<E<70 1.4516 1.4874 1.5828 1.7722 1.711 1.6235 
70<E<SO 1.4443 1.4777 1.5683 1.7509 1.6949 1.6134 
SO<E<90 1.436 1.4666 1.5513 1.7252 1.6751 1.6007 
90<E< 100 1.4265 1.4549 1.533 1.697 1.6532 1.5863 
100<E< 110 1.4135 1.4461 1.5196 1.6758 1.6365 1.575 
110 < E < 120 1.3888 1.4346 =1.5055 1.653 1.6184 1.5625 
120 <E< 140 1.4021 1.4184 1.4819 1.6155 1.5882 1.5411 
140 < E < 160 1.4489 1.4311 1.4566 
I 
1.5761 1.5561 1.5182 
160<E< ISO 1.4847 1.4733 1.4556 1.5484 1.5332 1.5013 
IS0<E<200 1.5456 1.5373 1.5128 1.531 1.5159 1.4875 
h 85 g/cm2 
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Table 29. Blood forming organs quality factors per energy range per aluminum density 
th h 15 / 2rougj gJcm 
BFO quality 
factor 
Aluminum 
Densities 
Energy range 
(MeV) 1 g/cm2 2 g/cm2 3 g/cm2 5 g/cm2 7 g/cm2 10 g/cm2 15 g/cm2 
0< E< 10 1.4057 1.4044 1.4049 1.4107 1.4206 1.4404 1.4821 
10<E<20 1.4057 1.4044 1.4049 1.4107 1.4206 1.4404 1.4821 
20<E<30 1.4075 1.4042 1.4047 1.4104 1.4202 1.4398 1.4814 
.30<E<40 1.4073 1.4041 1.4036 1.4091 1.4187 1.4379 
I 
1.4789 
40 <E < 50 1.4033 1.3919 1.402 1.4065 1.4246 1.4342 1.4739 
50<E<60 1.3772 1.3843 1.3878 1.4029 1.42 1.4284 1.4663 
60 <E <70 1.3532 1.377 1.3692 1.3857 1.405 1.421 1.4563 
70<E<SO 1.349 1.3561 1.3627 1.3721 1.3985 1.4147 1.4478 
SO<E<90 1.3462 1.3478 1.3556 1.3661 1.3837 1.4043 1.4378 
90<E<100 1.3444 1.3474 1.3513 1.3586 1.3691 1.3901 1.4266 
l00<E<110 1.3528 1.3537 1.3552 1.3596 1.3668 1.381 1.4164 
110<E<120 1.3696 1.3687 1.3675 1.3679 1.3701 1.3788 1.4051 
120 <E < 140 1.4017 1.4008 1.4001 1.3967 1.3931 1.3952 1.4041 
140<E<160 1.4493 1.4461 1.4429 1.4367 1.4309 1.4254 1.4203 
160<E<IS0 1.4872 1.485 1.4824 1.4767 1.4708 1.4618 1.4499 
lS0<E<200 1.5369 1.5364 1.5357 1.5338 1.531 1.5251 1.5148 
BFO quality 
factor 
Aluminum 
Densities 
Energy rangt: 
(MeV) 20 g/cm2 25 g/cm2 35 g/cm2 50 g/cm2 65 g/cm2 S5 g/cm2 
0< E < 10 1.532 1.5884 1.7165 1.9351 1.8051 1.6804 
10<E<20 1.532 1.5884 1.7165 1.9351 1.8051 1.6804 
20<E<30 1.5312 1.5874 1.7152 1.9336 1.8041 1.6799 
30<E<40 1.5281 1.5837 1.7106 1.9279 1.8004 1.6778 I 
40<E<50 1.5219 1.5764 1.7011 1.9163 1.7927 1.6735 
50<E<60 1.5123 1.565 1.6865 1.8981 1.7805 1.6665 
60<E<70 1.4998 1.55 1.6669 1.8734 1.7636 1.6566 
70 < E < SO 1.489 1.537 1.6497 1.8514 1.7484 1.6474 
SO<E<90 1.4763 1.5215 1.6288 1.8238 1.7287 1.6351 
90<E<100 1.4626 1.5047 1.6059 1.7929 1.7064 1.6208 I 
100<E<110 1.4524 1.4922 1.5886 1.769 1.6887 1.6091 
110 < E < 120 1.4409 1.479 1.57 1.7428 1.6691 1.5957 
120 < E < 140 1.4266' 1.4575 1.5396 1.6984 1.6352 1.5721 
140 < E < 160 1.4242 1.441 1.5079 1.6506 1.5984 1.5461 
160 < E < ISO 1.4439 1.4467 1.4891 1.6158 1.5713 1.5266 
lS0<E<200 1.5057 1.4973 1.4988 1.5694 1.5344 1.4993 
Table 30. Blood forming organs quality factors per energy range per aluminum density 
through 85g/cm2 
. 
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8.3 FIGURES 
Figure 1. Skin absorbed dose per energy range per aluminum density 
Skin Absorbed Dose per energy range according to AI density 
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Figure 2. Skin dose equivalent per energy range per aluminum density 
Skin Absorbed Dose Equivalent per energy range according to AI density 
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Figure 3. Eye absorbed dose per energy range per aluminum density 
Eye Absorbed Dose per energy range according to AI density 
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Figure 4. Eye dose equivalent per energy range per aluminum density 
Eye Absorbed Dose Equivalent per energy range according to AI density 
300 rl----,----,,----.----.-----.----.-----,----.----.-----,----.-----.----------,---------.----------,---------~ 
250 
200 
>Cf) 
~ 
'E 
Q) 
co 150>
'S 
C" 
Q) 
Q) 
8 
en 
100 
50 
0 ' I ' I ' I e 1 _ , _ 1 _ 
10 20 30 40 50 60 70 80 90 100 110 120 140 160 180 , 200 
Energy ranges MeV 
-
_1g
5g-_ 2g3g 
_ 7g 
_ 10g 
_ 15g 
c=J 20g 
c=J 25g 
c:=:::J 35g 
_ 50g
- 65g 

_ 85g 
37 
Figure 5. Blood forming organs absorbed dose per energy range per aluminum density 
Blood Forming Organs Absorbed Dose per energy range according to AI density 
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Figure 6. Blood forming organs dose equivalent per energy range per aluminum density 
Blood Forming Organs Absorbed Dose Equivalent per energy range according to AI density 
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Figure 7. Skin absorbed dose p~r energy range per aluminum density through 15 g/cm2 
Skin Absorbed Dose per energy range according to AI density 
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Figure 8. Skin dose equivalent per energy range per aluminum density through 15 g/cm2 
Skin Absorbed Dose Equivalent per energy range according to AI density 
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Figure 9. Eye absorbed dose per energy range per aluminum density through 15 g/cm2 
Eye Absorbed Dose per energy range according to AI density 
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· Figure 10. Eye dose equivalent per energy range per aluminum density through 15 g/cm2 
Eye Absorbed Dose EquiVcilent per energy range according to AI density 
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Figure 11. Blood forming organs absorbed dose per energy range per aluminum density through 15 g/cm2 
Blood Forming Organs Absorbed Dose per energy range according to AI density 
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Figure 12. Blood forming organs dose equivalent per energy range per aluminum density through 15 g/cm2 
Blood Forming Organs Absorbed Dose Equivalent per energy range according to AI density 
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Figure 13. Skin absorbed dose per energy range per aluminum density through 85 g/cm2 
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Figure 14. Skin dose equivalent per energy range per aluminum density through 85 g/cm2 
Skin Absorbed Dose Equivalent per energy range according to AI density 
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Figure 15. Eye absorbed dose per energy range per aluminum density through 85 g/cm2 
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Figure 16. Eye dose equivalent per energy range per aluminum density through 85 g/cm2 
Eye Absorbed Dose Equivalent per energy range according to AI density 
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Figure 17. Blood forming organs absorbed dose per energy range per aluminum density through 85 g/cm2 
Blood Forming Organs Absorbed Dose per energy range according to AI density 
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Figure 18. ·Blood forming organs dose equivalent per energy range per aluminum density through 85 g/cm2 
Blood Forming Organs Absorbed Dose Equivalent per energy range according to AI density 
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Figure 19. Skin absorbed dose per energy range per aluminum density through 85 g/cm2 
Skin Absorbed Dose per energy range according to AI density 
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Figure 20. Skin dose equivalent per energy range per aluminum density through 85 g/cm2 
Skin Absorbed Dose Equivalent per energy range according to AI density 
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Figure 21. Skin absorbed dose per energy range per aluminum density through 85 g/cm2 
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Figure 22. Skin dose equivalent per energy range per aluminum density through 85 glcm2 
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Figure 23. Skin absorbed dose per energy range per aluminum density through 15 glcm2 
Skin Absorbed Dose per energy range according to AI density 
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Figure 24. Skin dose equivalent per energy range per aluminum density through 15 g/cm2 
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Figure 25. Eye absorbed dose per energy range per aluminum density through 15 g/cm2 
Eye Absorbed Dose per energy range according to AI density 
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Figure 26. Eye dose equivalent per energy range per aluminu~ density through 15 g/cm2 
Eye Absorbed Dose Equivalent per energy range according to AI density 
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8.4 MATLAB CODE 
% Caleb Bastian NE 598 

clc; 
clear all; 
max1=110i 
% load data 

load ( , gl' ) ; 

load( 'g2') i 

load ( 'g3 ' ) ; 

load ( I g3 5 I ) ; 

load ( 'g5 ' ) i 

load ( 'g7 ' ) i 

load ( 'g10' ) i 

load ( 'g15' ) i 

load ( , g2 0 ' ) i 

load ( , g2 5 ' ) i 

load ( Ig50 I) i 

load ( Ig65 I) i 

load ( ! g8 5 I ) i 

ind_dose=[2 5 8] i 

ind_doseq=[3 6 9] i 

ticks=[10:10:maxl 120:20:200] i 

energies=[5:10: (maxl-5) 115 130:20:190] i %[0 10 20 30 40 50 60 70 80] i 

% Get doses by Al density 

skindose=horzcat (gl ( : , 2) , g2 ( : , 2) , g3 ( : , 2) , g5 ( : , 2) , g7 ( : , 2) , gl 0 ( : , 2) , g15 ( : , 2) ... 

, g20 ( : ,2) , g25 ( : ,2) , g35 ( : ,2) , g50 ( : ,2) , g65 ( : ,2) , g85 ( : ,2) } i 

skindose_eq=horzcat (gl ( : ,3) , g2 ( : ,3) , g3 ( : (3) , g5 ( : ,3) , g7 ( : ,3) , g10 ( : ,3) , g15 ( : ,3) . 

, g20 ( : ,3) , g25 ( : ,3) , g35 ( : ,3) , g50 ( : ,3) , g65 ( : ,3) , g85 ( : ,3) ) i 

skin_QF horzcat (gl (: ,4) ,g2 (: (4) ,93 (: ,4) ,g5 (: ,4) ,g7 (:,4) ,g10 (:,4) ,915 (:,4) ... 
, g20 ( : ,4) , g2 5 ( ,4),935 ( : ,4) , g50 ( : ,4) , g65 ( : ,4) ,985 ( : ,4) ) ; 
eyedose=horzcat {gl ( : , 5) , g2 (: , 5) , g3 ( : ,5) ,95 ( : ,5) , g7 ( : ,5) , g10 ( : ,5) , g15 ( : ,5) ... 

, g2 0 ( : , 5) , g2 5 ( : , 5) , g3 5 ( : , 5) , g5 0 ( : , 5) , 9 65 ( : , 5) , 9 8 5 ( : , 5) ) i 

eyedose_eq=horzcat (gl (:,6) ,g2 (:,6) ,g3 (:,6) ,g5 (:,6) ,g7 (:,6) ,g10 (:,6) ,g15 (:,6) '" 

, g20 ( ; ,6) , g2 5 ( : ,6) , g35 ( : ,6) , g50 ( : ,6) , g65 ( : ,6) , g8 5 ( : (6) ) i 

eye_QF == horzcat (gl ( : ,7) , g2 ( : , 7) , g3 ( : ,7) , g5 ( : ,7) , g7 ( : ,7) , g10 ( : ,7) , g15 ( : , 7) ... 
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,g20 (:,7) ,g25 (:,7) ,g35 (:,7) ,g50 (:,7) ,g65 (:,7) ,g85 (:,7)) ; 
BFOdose=horzcat (gl (: ,8) ,g2 (: ,8) ,g3 (:,8) ,g5 (:,8) ,g7 (: ,8) ,g10 (:,8) ,g15 (: ,8) ... 
, g2 0 ( : , 8) , g2 5 ( : , 8) , g3 5 ( : , 8) , g5 0 ( : , 8) , g6 5 ( : , 8) , g8 5 ( : , 8) ) ; 
BFOdose_eq=horzcat (gl (:,9) ,g2 (: ,9) ,g3 (: ,9) ,g5 (: ,9) ,g7 (: ,9) ,g10 (: ,9) ,g15 (: ,9) ... 
, g20 ( : ,9) , g25 ( : , 9) , g3 5 ( : ,9) , g50 ( : ,9) , g65 ( : ,9) , g85 ( : , 9) ) ; 
BFO_QF horzcat (gl (: ,10) ,g2 (: ,10) ,g3 (: ,10) ,g5 (: ,10) ,g7 (: ,10) ,g10 (: ,10) ,g15 (: ,10) ... 

,g20(:,10) ,g25(:,10) ,g35(:,10) ,g50(:,10) ,g65(:,10) ,g85(:,10)) i 

% doses in the energy ranges across the Al densities (from the energy the 

% calculation was run at to 2500 MeV) 

for ii=2:1:length(skindose(:,l))) 

skin_dose (ii-1, :)=skindose(l, :)-skindose(ii,:) i 

skin_dose_eq(ii-1, :)=skindose_eq(l, :)-skindose_eq(ii, :)i 

eye_dose (ii-1, :)=eyedose(l, :)-eyedose(ii, :)i 

BFo_dose_eq(ii-l, :)=BFOdose_eq(l, :)-BFOdose_eq(ii, :)i 

eye_dose_eq(ii-1, :)=eyedose_eq(l, :)-eyedose_eq(ii,:) i 

BFO_dose(ii-l, :) =BFOdose (1, :)-BFOdose(ii,:) i 

end 
% Get quality factors 
for 	ii=2:1:length(skin_QF(:,l))) 

skinQF (ii-1, :) (skin_QF (ii-I, :) +skin_QF (ii, :)) /2 i 

eyeQF(ii ,:) (eye_QF(ii-l, :)+eye_QF(ii,:) )/2; 

BFOQF(ii-l, :)=(BFO_QF(ii-l, :)+BFO_QF(ii, :))/2i 

end 

% Gets the actual doses in the energy ranges 

% 0 < E < 10 

sdeq(l, :)=skin_dose_eq(l, :)i 

ed(l, :)=eye_dose(l, :)i 

BFOd(l, :)=BFO_dose(l, :)i 

BFOdeq(l, :)=BFO_dose_eq(l,:); 

sd(l, :)=skin_dose(l,:) i 

edeq(l, :)=eye_dose_eq(l,:) i 

for 	ii=2:1:length(skin_dose(:,l)) 

sd (ii, :) =skin_dose (ii, :) -skin_dose (ii-1, :) i 

sdeq(ii, :)=skin_dose_eq(ii, :)-skin_dose_eq(ii-1,:) 
edeq(ii, :)=eye_dose_eq(ii, :)-eye_dose_eq(ii-l, :)i 

i 

ed(ii, :)=eye_dose(ii, :)-eye_dose(ii-l,:) i 

BFOd(ii, :)=BFO_dose(ii, :)-BFO_dose(ii ,:) i 

BFOdeq(ii, :)=BFO_dose_eq(ii,:) -BFO_dose_eq(ii-l,:) i 

end 
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%percentage contribution 
for 	ii=l: 1: 13 
sum_sd=sum(sd(:,ii») i 
sd~erc(:,ii)=sd(:,ii) ./sum_sdj 
sum_sdeq=sum(sdeq(:,ii) i 
sdeq~erc(:,ii)=sdeq(:,ii) ./sum_sdeqj 
sum_ed=sum(ed(:,ii» i 

ed~erc(:,ii)=ed(:,ii) ./sum_ed; 

sum_edeq=sum(edeq(:,ii» i 

ede~erc(:,ii)=edeq(:,ii) ./sum_edeqi 

sum_BFOd=sum(BFOd(:,ii» ; 

BFOd~erc(:,ii)=BFOd(:/ii) ./sum_BFOd; 

sum_BFOdeq=sum(BFOdeq(:,ii»; 

BFOde~erc(:,ii)=BFOdeq(:,ii) ./sum_BFOdeq; 

end 
% Graph the doses according to energy range 

figure (1) i 

bar(energies,abs(sd» 

title('Skin Absorbed Dose per energy range according to Al density') 

set (gca, I xtick I ticks)
I 
xlabel('Energy ranges MeV'); ylabel(IAbsorbed Dose (cGy) ,) i 

legend ( 'lg' I '2g I, '3g I, '5g' , I 7g' 1 I109' , I 15g' , I 20g I, '25g' , '35g I, I50g' ... 

I '65g', '85g', '100g', '125g' I '150g', '200g', '225g', '250g',-1); 
figure (2) i 

bar(energies,abs(sdeq» 

title('Skin Absorbed Dose Equivalent per energy range according to Al density') 

set (gca, 'xtick',ticks) 

xlabel('Energy ranges MeV') i ylabel('Dose equivalent (cSv) ,) i 

legend ('lg' , 1 2g' , '3g' , '5g' , '7g' , 'lOg' , '15g' , '20g' , I 25g' , '35g' , '50g' ... 

I '65g'l '85g', '100g'I '125g', '150g', '200g', '225g', '250g',-1) i 
figure(3); 
bar(energies,abs(ed» 
title('Eye Absorbed Dose per energy range according to Al density') 
set(gca, 'xtick',ticks) 
xlabel('Energy ranges MeV'); ylabel('Absorbed Dose (cGy) '); 
legend ( 'lg' 1 '2g' , '3g' 1 '5g' , '7g' , 'lOg' , '15g' 1 '2 Og 'I '25g I, '35g' , ' 50g I ... 
, '65g' I I 8 5g I 1 ' 10 Og I , '12 5g' , ' 15 Og , , '20 Og' , '22 5g , , ! 25 og' , -1) i 
figure (4) i 
bar(energies/abs(edeq» 
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title('Eye Absorbed Dose Equivalent per energy range according to Al density') 

set (gca, 'xtick',ticks) 

xlabel('Energy ranges MeV'); ylabel('Dose equivalent (cSv) ,) i 

legend ( 'lg', '2g', '3g', 'sg', '7g', 'lOg', 'lSg', '20g', '2Sg', '3Sg', 'SOg' ... 

,'6Sg', '8Sg', '100g', '12Sg','lS0g', '200g', '22Sg', '2S0g',-1) i 
figure(S) i 

bar(energies,abs(BFOd}) 

title('Blood Forming Organs Absorbed Dose per energy range according to Al density') 

set (gca, 'xtick' ,ticks) 

xlabel('Energy ranges MeV'): ylabel('Absorbed Dose (cGy) ,) i 

legend (' 19' , '2g' , '3g' , 'Sg! , '7g' , 'lOg' , 'lSg' , '20g' , '2Sg' , '3Sg' , 'SOg' ... 

,'6Sg', '8Sg', '100g', '12Sg', 'lS0g', '200g', '22Sg', '2S0g', 1) i 
figure(6); 

bar (energies, abs (BFOdeq) ) 

title('Blood Forming Organs Absorbed Dose Equivalent per energy range according to Al 

density' ) 

set (gca, 'xtick',ticks) 

xlabel('Energy ranges MeV'); ylabel('Dose equivalent (cSv) ,); 

legend ( , 19' , '2g' , ' 3g , , 'Sg I , I 7g I , 'lOg' , 'lSg' , '2 Og' , ! 2 Sg' , '3 Sg' , ' S Og , ... 

,'6Sg', '8Sg', '100g', '12Sg', '150g', '200g', '22Sg', '250g' ,-1) i 
figure (7) ; 

bar(energies,abs(sd(:,l:7») 

title('Skin Absorbed Dose per energy range according to Al density') 

set(gca, 'xtick',ticks) 

xlabel('Energy ranges MeV') ;ylabel('Absorbed Dose (cGy) ,); 

legend ('lg' , '2g' , '3g' , 'Sg' , '7g' , 'lOg' , 'lSg' , '20g' , '2Sg' , '3Sg' , 'SOg' ... 

,'6Sg', '8Sg', '100g', '12Sg', 'lS0g', '200g', '22Sg', '2S0g',-1) i 
figure(8); 

bar(energies,abs(sdeq(:,l:7) » 

title('Skin Absorbed Dose Equivalent per energy range according to Al density') 

set(gca, 'xtick',ticks) 

xlabel('Energy ranges MeV') i ylabel('Dose equivalent (cSv) ') i 

legend (, 19' , '2g' , '3g' , I 5g' , '7g I, 'lOg' J '15g' , '20g! J '25g' , '3Sg' , 'SOg' ... 

, '6 5g , J ' 8Sg' , ' 10 Og' , '12 Sg' , ' 15 Og' , '20 Og' , , 22 5g , , '25 Og' , -1) i 
figure(9); 
bar(energies,abs(ed(:,l:7») 
title('Eye Absorbed Dose per energy range according to Al density') 
set (gca, 'xtick' ,ticks) 
xlabel('Energy ranges MeV') i ylabel('Absorbed Dose (cGy) ,) i 
legend ( I 19 I 2g' , '3g' , '5g' , '7g' , 'lOg' , '15g' , '20g' I '25g' I '35g' , '50g' ...I I 
'6Sg', '8Sg', '100g', '12Sg', '15009', '200g', '225g', '2S0g' ,-1) i 
figure (10) i 
I 
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bar(energies,abs(edeq(:,l:7) » 

title('Eye Absorbed Dose Equivalent per energy range according to Al density') 

set(gca, 'xtick',ticks) 

xlabel('Energy ranges MeV'); ylabel('Dose equivalent (cSv) '); 
legend {'lg', '2g', '3g', 15g l , '7g', 'lOg', '15g', '20g', '25g', '35g',"50g' ... 
,'65g', '85g', '100g', '125g', '150g' ,'200g', '225g', '250g' ,-1) i 
figure (11) i 
bar(energies,abs(BFOd(:,l:7») 

title('Blood Forming Organs Absorbed Dose per energy range according to Al density') 

set (gca, 'xtick',ticks) 

xlabel('Energy ranges MeV'); ylabel('Absorbed Dose (cGy) '); 
legend ( I 19' , '2g' , '3g' , '5g' , '7g' , 'lOg' , '15g' , '20g' , I 25g' , '35g' , '50g' ... 
,'65g', '85g' 1 '100g', '125g', '150g', '200g', '225g', '250g',-1); 
figure (12) ; 
bar(energies,abs(BFOdeq(:,l:7») 

title('Blood Forming Organs Absorbed Dose Equivalent per energy range according to Al 

density' ) 

set (gca, 'xtick',ticks) 

xlabel('Energy ranges MeV'); ylabel('Dose equivalent (cSv) '); 
legend ( 'lg' , '2g' , '3g' , '5g' , '7g' , 'lOg' , , 15g' , '20g' , '25g' , '35g' , '50g' ... 
, '65g', '85g', '100g', '125g','150g', '200g', '225g', '250g',-1) i 
figure (13) i 
bar(energies,abs(sd(:,8:13)}) 
title('Skin Absorbed Dose per energy range according to Al density') 
set (gca, 'xtick',ticks} 
xlabel('Energy ranges MeV'} ; ylabel('Absorbed Dose (cGy) ') ; 
%legend ( 'lg' , '2g' , '3g' , '5g t , '7g' , 'lOg' , '15g' , ... 
legend('20g', '25g' I '35g', '50g', '65g', '85g' ,-1); 
%, '100g' I '125g', '150g' 1 '200g', '225g', '250g') i 
figure (14) i 
bar(energies,abs(sdeq(:,8:13») 

title('Skin Absorbed Dose Equivalent per energy range according to Al density') 

set(gca, 'xtick',ticks) 

xlabel('Energy ranges MeV') iylabel('Dose equivalent (cSv) ,) i 

%legend ( 'lg' , '2g' I '3g' , '5g' , r 7g' , r 109' , '15g' , ... 

legend ( '20g', '25g' I '35g' I '50g', '65g', '85g',-1) ; 

%, '100g', '125g', '150g', '200g', '225g', '250g') i 

figure(15) ; 

bar(energies,abs(ed(:,8:13») 

title('Eye Absorbed Dose per energy range according to Al density') 

set (gca, 'xtick',ticks) 

xlabel('Energy ranges MeV') i ylabel('Absorbed Dose (cGy) ') i 
%legend ( 'lg' , '2g' , '3g r , , 5g' , 1 7g " 'lOg' , '15g' , ... 
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legend('20g', '25g', '35g', '50g', '65g', '85g' ,-1); 
%, '100g', '125g', '150g', '200g', '225g', '250g') i 
figure(16) ; 
bar(energies / abs(edeq(:,8:13))) 
title('Eye Absorbed Dose Equivalent per energy range according to Al density') 
set (gca, 'xtick',ticks) 
xlabel(IEnergy ranges MeV'); ylabel('Dose equivalent (cSv) ,) i 
%legend ( 'lg I, '2g' , '3g' , , 5g' , '7g' , 'lOg' , , 15g' , ... 
legend('20g', '25g', '35g', '50g' ,'65g', '85g' ,-1); 
%, '100g', '125g', '150g', '200g'I '225g', '250g') i 
figure (17) i 
bar(energies,abs(BFOd(:,8:13))) 
title('Blood Forming Organs Absorbed Dose per energy range according to Al density') 
set (gca, 'xtick',ticks) 
xlabel('Energy ranges MeV') i ylabel('Absorbed Dose (cGy) ') i 
%legend ( 'lg' , '2g' , '3g' , '5g' , '7g' , 'lOg' , '15g' , ... 
legend ( '20g' 1 '25g' , 1 35g' , '50g' , '65g' , '85g' , -1) i 
%, '100g' , '125g' , '150g' , '200g' , '225g I, '250g I) i 
figure (18) i 
bar(energies,abs(BFOdeq(:,8:13))) 
title('Blood Forming Organs Absorbed Dose Equivalent per energy range according to Al 
density' ) 
set (gca, 'xtick',ticks) 
xlabel('Energy ranges MeV'); ylabel('Dose equivalent (cSv) '); 
%legend( 'lg', '2g', '3g',' 5g', '7g', 'lOg', '15g', ... 
legend('20g', '25g', '35g', '50g', '65g', '85g',-1); 
%, '100g', '125g', '150g', '200g', '225g', '250g') i 
figure (19) ; 
subplot(2,l/1); 
bar (energies (1:7) ,abs(sd(1:7, :))) 
title('Skin Absorbed Dose per energy range according to Al density') 
set (gca, 'xtick',ticks(1:7)) 
xlabel('Energy ranges MeV'); ylabel('Absorbed Dose (cGy) ,) i 
legend ( 'lg' 1 '2g' / '3g' , '5g' , '7g' , 'lOg' , '15g' , '20g' , '25g' , '35g' , '50g' ... 
, '65g', '85g' / '100g', '125g', '150g', '200g', '225g', '250g',-1); 
subplot(2,l,2) i 
bar (energies (8:16) ,abs(sd(8:16, :))) 
title('Skin Absorbed Dose per energy range according to Al density') 
set (gca l 'xtick',ticks(8:16)) 
xlabel('Energy ranges MeV') i ylabel('Absorbed Dose (cGy) ') i 
legend ( , 19' , '2g' , '3g' , '5g' , '7g' / 'lOg' , '15g' , '20g' , '25g' , '35g' , '50g' ... 
/ '65g'/ '85g', '100g' / '125g', '150g', '200g', '225g', '250g',-1); 
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figure (20) i 

subplot(2,l, 

bar (energies ( :7},abs(sdeq(1:7, :»} 

title('Skin Absorbed Dose Equivalent per energy range according to Al density'} 

set (gca, 'xtick' ,ticks (1: 7» 

xlabel('Energy ranges MeV'); ylabel('Dose equivalent (cSv) '); 

legend ( 'lg' I '2g' I '3g' , '5g' , '7g' I 'lOg' , '15g' , '20g' I '25g' , '35g' , '50g' ... 

1 '65g', '85g', '100g', '125g', '150g', '200g', '225g', '250g' ,-1); 
subplot(2 / 1 / 2) ; 
bar(energies(8:16) labs(sdeq(8:16, :»} 

title('Skin Absorbed Dose Equivalent per energy range according to Al density') 

set (gca, 'xtick',ticks(8:16» 

xlabel ('Energy ranges MeV'); ylabel('Dose equivalent (cSv) ,) i 

legend ( 'lg' '2g'I '3g', '5g'I '7g', 'lOg', '15g'I '20g'I '25g', '35g' 1 '50g' ...
1 
1 '65g', '85g', '100g', '125g', '150g', '200g', '225g', '250g',-1) i 
figure (21) i 

subplot (2 1 ,1); 

bar(energies(1:9),abs(ed(1:9 :}»
1 
title('Eye Absorbed Dose per energy range according to Al density') 

set (gca, 'xtick',ticks(1:9» 

xlabel ('Energy ranges MeV') iylabel('Absorbed Dose (cGy) '); 

legend ( 'lg' , '2g' 1 '3g' , '5g' I '7g' 1 'lOg' , '15g' , '20g' , '25g' , '35g' , '50g' ... 

,'65g'l '85g', '100g' 1 '125g', '150g', '200g', '225g', '250g'I-1); 
subplot (2, ,2) i 
bar(energies(10:16),abs(ed(10:16 :})}1 
title('Eye Absorbed Dose per energy range according to Al density'} 

set (gca l 'xtick',ticks(10:16» 

xlabel ('Energy ranges MeV'}; ylabel('Absorbed Dose (cGy) ') i 

legend ( 'lg', '2g' 1 '3g', '5g', '7g', 'lOg', '15g', '20g'l '25g', '35g', '50g' ... 

,'65g', '85g', '100g', '125g', '150g'l '200g', '225g', '250g'/- 1 ) i 
figure (22) i 

subplot(2,l,l) i 

bar (energies (1:9) ,abs(edeq(1:9, :») 

title('Eye Absorbed Dose Equivalent per energy range according to Al density') 

set (gca, 'xtick',ticks(1:9» 

xlabel('Energy ranges MeV'); ylabel('Dose equivalent (cSv) '); 

legend ( 'lg' , '2g' , '3g' , '5g' , '7g' , 'lOg' , '15g' , '20g' , '25g' , '3 5g' , ' 50g' ... 

, '6 5g' , ' 8 5g' , '10 Og , , '12 5g' , ' 15 Og , , '20 Og' , ' 22 5g , , '25 Og' , -1) ; 
subplot(2,l,2) i 
bar(energies(10:16),abs(edeq(10:16 :»)1 
title('Eye Absorbed Dose Equivalent per energy range according to Al density') 

set (gca, 'xtick'/ticks(10:16» 

xlabel('Energy ranges MeV'); ylabel('Dose equivalent (cSv) ') i 

legend ( 'lg', '2g', '3g', '5g', '7g', 'lOg', '15g', '20g', '25g', '35g', '50g' ... 

,'65g', '85g', '100g', '125g', '150g', '200g', '225g', '250g', -1); 
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figure(23}; 

subplot(2,1,1}; 

bar{energies(1:7),abs(sd(1:7,1:7})} 

title('Skin Absorbed Dose per energy range according to Al density') 

set(gca, 'xtick',ticks(1:7)} 

xlabel('Energy ranges MeV'}; ylabel('Absorbed Dose (cGy) ') i 

legend ( , 19' , '2g' , ' 3g , , '5g' , ' 7g , , 'lOg' , , 15g , , '2 Og , , '2 5g' , '3 5g , , , 5 Og' ... 

,'65g', '8Sg', '100g', '125g', '150g', '200g', '225g', '250g' ,-1); 
subplot(2,l,2} ; 
bar(energies(8:16) ,abs(sd(8:16,l:7») 
title('Skin Absorbed Dose per energy range according to Al density'} 
set (gca, 'xtick' ,ticks(8:16}} 
xlabel('Energy ranges MeV'); ylabel('Absorbed Dose (cGy) '); 
legend ( 'lg' , '2g' , '3g' , 'Sg' , '7g' , 'lOg' , 'lSg' , I 20g' , '2Sg' , '35g' , '50g' ... 
, '65g', '85g', '100g', '125g', '150g', '200g', '225g', '250g' ,-1); 
figure (24) i 

subplot(2,l,l}; 

bar(energies(1:7) ,abs(sdeq(1:7,l:7}» 

title('Skin Absorbed Dose Equivalent per energy range according to Al 

set (gca, 'xtick',ticks(1:7}) 

xlabel('Energy ranges MeV') i ylabel('Dose equivalent (cSv) ') i 

legend (, 19' , '2g' , '3g' , '5g' , '7g' , 'lOg' , '15g' , '20g' , '25g' , '35g' , '50g' ... 

, '65g',' 8Sg', '100g', '125g', 'lS0g', '200g', '225g', '250g' ,-1) i 
subplot(2,l,2) ; 
bar(energies(8:16) ,abs(sdeq(8:16,l:7»} 
title('Skin Absorbed Dose Equivalent per energy range according to Al 
set (gca, 'xtick',ticks(8:16}) 
xlabel('Energy ranges. MeV'); ylabel('Dose equivalent (cSv) ,} i 
legend ( 'lg', '2g', '3g', 'Sg', '7g', 'lOg', '15g', '20g', '2Sg', '35g', '.50g' ... 
,'65g', '85g', '100g', '125g', '150g', '200g', '225g', '2S0g',-1) i 
figure (2S) ; 

subplot(2,1,1) i 

bar (energies (1:9) ,abs(ed(1:9,l:7») 

title('Eye Absorbed Dose per energy range according to Al density') 

set (gca, 'xtick',ticks(1:9» 

xlabel('Energy ranges MeV') i ylabel('Absorbed Dose (cGy)'); 

legend ( 'lg', '2g', '3g', '5g', '7g', 'lOg', '15g', '20g', '25g', '35g', '50g' ... 

, , 65g' , ' 8 5g! , '10 Og , , ! 125g! , I 15 Og , , '20 Og I , '22 5g' , '25 Og' , -1) ; 
subplot(2,l,2) i 
bar{energies(10:16),abs(ed(10:16,1:7})} 
title('Eye Absorbed Dose per energy range according to Al density') 
set (gca, 'xtick',ticks(10:16» 
xlabel('Energy ranges MeV') i ylabel('Absorbed Dose (cGy) '); 
legend ( , 19' , I 2g' , '3g' , , 5g I , '7g' , 'lOg' , '15g' , I 2Og I , '2 5g , , '3 5g I , 'S Og , ... 
density') 
density') 
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,'65g', '85g', '100g', '125g', '150g', '200g', '225g', '250g',-1); 
figure (26) i 

subplot(2,l,l) i 

bar(energies(1:9),abs(edeq(1:9,l:7))) 

title('Eye Absorbed Dose Equivalent per energy range according to Al density') 

set (gca, 'xtick',ticks(1:9)) 

xlabel('Energy ranges MeV'); ylabel('Dose equivalent (cSv) ') i 

legend ( 1 19' , '2g' I '3g' I '5g' , '7g' , 'lOg' I '15g' , '20g' , '25g' , '35g' , '50g' ... 

,'65g', '85g', '100g', '125g', '150g', '200g', '225g', '250g',-l) i 

subplot(2,l,2) i 

bar (energies (10:16) ,abs(edeq(10:16,l:7))) 

title('Eye Absorbed Dose Equivalent per energy range according to Al density') 

set(gca, 'xtick',ticks(10:16)) 

xlabel ( 'Energy ranges MeV'); ylabel ( 'Dose equivalent (cSv)'); 

legend ( 'lg', '2g', '3g', '5g', '7g', 'lOg', '15g', '20g', '25g', '35g', '50g' ... 

,'65g', '85g', '100g', '125g', '150g', '200g', '225g', '250g',-1) i 

68 
8.5 VARIABLES LOADED INTO MATLAB 

g1.mat 
o 775.75 1439.6 1.8558507.73 847.12 1.668447.89967.332 1.4057 
10 775.75 1439.6 1.8558507.73 847.12 1.668447.89967.332 1.4057 
20 775.75 1439.6 1.8558507.73 847.12 1.668447.89867.331 1.4057 
30 441.3 536.73 1.2162406.81 574.64 1.412648.044 67.707 1.4093 
40 254.24323.48 1.2723344.5 472.59 1.371848.09767.595 1.4054 
50 148.79 187.36 1.2592 162.18 192.3 1.185747.56566.652 1.4013 
60 91.001118.23 1.2992 101.2 126.51 1.2501 44.19959.808 1.3532 
70 61.64382.717 1.341964.06483.3191.300638.61652.256 1.3532 
80 50.24868.135 1.355 51.245 67.757 1.322233.88 45.564 1.3449 
90 33.17845.906 1.383632.57244.378 1.362525.00233.6911.3475 
100 25.78935.907 1.392325.61935.292 1.3776 19.99326.816 1.3413 
110 19.841 28.123 1.417420.08728.112 1.3995 15.91521.714 1.3644 
120 15.19721.865 1.4388 15.45621.895 1.416612.38 17.02 1.3748 
140 8.3916 12.508 1.4905 8.4338 12.383 1.46836.53479.3356 1.4286 
160 6.088 9.267 1.52226.0785 9.121 1.50054.62536.7996 1.4701 
180 4.36466.7725 1.55174.35786.66641.52983.2951 4.9568 1.5043 
200 2.11153.4156 1.61762.1401 3.3964 1.5871 1.61352.5325 1.5695 
g2.mat 
o 389.3 652.65 1.6765296.92459.13 1.5463 39.96656.13 1.4044 
10 389.3 652.65 1.6747296.92459.13 1.546339.96656.13 1.4044 
20 389.3 652.65 1.6765296.92459.13 1.5463 39.96656.129 1.4044 
30 389.3 652.59 1.6763296.92459.08 1.546239.96456.106 1.4039 
40 274.19336.35 1.2267262.18363.57 1.386740.00756.181 1.4043 
50 146.94 t'82.29 1.2406 174.6 203.641.166339.86355.713 1.3796 
60 89.553 116.54 1.3013 99.714 127.611.279839.217 54.474 1.389 
70 57.13376.32 1.335861.20279.013 1.291 34.65947.309 1.365 
80 46.36862.616 1.350448.53 63.799 1.314631.43342.344 1.3471 
90 30.41442.157 1.3861 30.551 41.492 1.3581 23.57431.79 1.3486 
100 24.12633.706 1.3971 24.10433.19 1.3769 19.47626.219 1.3462 
110 18.52926.292 1.419 18.79526.293 1.399 15.32920.866 1.3612 
120 14.29520.632 1.4433 14.58920.698 1.4188 12.099 16.651 1.3762 
140 8.0064 11.973 1.49548.0512 11.832 1.46966.45699.2032 1.4253 
160 5.82268.8954 1.5277 5.8084 8.7271 1.50254.53556.6531 1.4669 
180 4.19546.5361 1.55794.17546.40041.53293.22334.8448 1.5031 
200 2.04623.3228 1.62392.0658 3.286 1.5906 1.5738 2.4703 1.5696 
69 
g3.mat 
o 247.57396.4 1.6011 203.37 304.24 1.496 33.93647.678 1.4049 
10 247.57 396.4 1.6011 203.37 304.24 1.496 33.93647.678 1.4049 
20 247.57396.39 1.6011 203.37 304.24 1.496 33.93647.677 1.4049 
30 247.57396.34 1.6009203.37304.2 1.495833.93347.655 1.4044 
40 247.56396.23 1.6006203.36304.08 1.495333.92647.593 1.4029 
50 157.83200.33 1.2693 176.27244.84 1.389 33.95 47.57 1.4012 
60 90.063 115.15 1.278599.84 121.941.221333.71547.017 1.3745 
70 54.89472.748 1.325259.98676.7614.279631.08242.395 1.364 
80 44.24659.666 1.348546.97261.46 1.308429.001 39.485 1.3615 
90 28.561 39.49 1.382729.228 39.56 1.353522.29530.092 1.3497 
100 22.78531.865 1.398522.98931.613 1.375118.77225.398 1.353 
110 17.521 24.803 1.4157 17.85724.913 1.3951 14.85420.164 1.3575 
120 13.499 19.48 1.443 13.86 19.655 1.4182 11.77 16.211 1.3774 
140 7.6416 11.43 1.49587.7062 11.319 1.46886.38199.0795 1.4227 
160 5.568 8.5098 1.52835.5608 8.3526 1.5021 4.46 6.5258 1.4632 
180 4.02636.2792 1.55964.00186.1382 1.53383.15744.7415 1.5017 
200 1.9777 3.2152 1.6258 1.9919 3.1715 1.5922 1.537 2.4125 1.5696 
gS.mat 
o 130.96200.81 1.534 115.84 168.111.451325.40235.835 1.4107 
10 130.96200.811.5334115.84168.111.451325.40235.8351.4107 
20 130.96200.81 1.5334 115.84 168.11 1.4513 25.402 35.835 1.4107 
30 130.96200.761.5331115.83168.311.451 25.4 35.8141.41 
40 130.95200.67 1.5324 115.82 167.97 1.450225.393 35.757 1.4081 
50 130.93200.51 1.5314 115.8 167.79 1.449 25.37935.656 1.4049 
60 104.63 136.99 1.3093 107.41 147.43 1.372625.36635.533 1.4008 
70 54.14770.997 1.311259.60475.709 1.270225.07 34.861 1.3705 
80 41.99256.062 1.3351 45.927 59.483 1.2952 24.004 32.975 1.3737 
90 26.271 36.172 1.376927.471 36.966 1.3456 19.815 26.919 1.3585 
100 20.88629.153 1.395821.42229.315 1.3685 17.04323.156 1.3587 
110 16.32423.037 L411216.648 23.1391.3899 14.064 19.133 1.3604 
120 12.39 17.791 1.4359 12.801 18.094 1.4134 11.061 15.213 1.3753 
140 7.0296 10.493 1.49287.1626 10.489 1.4644 6.2193 8.8194 1.4181 
160 5.1321 7.8283 1.52545.15947.7292 1.4981 4.34656.3252 1.4552 
180 3.71635.7942 1.55923.69865.6708 1.53323.04144.5567 1.4982 
200 1.8451 3.0007 1.6263 1.85282.9532 1.5939 1.471 2.3086 1.5694 
70 
g7.mat 
o 81.903 123.16 1.503875.294 107.93 1.4335 19.69 27.397 1.4206 
10 81.903 123.161.503875.293 107.93 1.4335 19.69 27.973 1.4206 
20 81.902 123.16 1.503775.293 107.93 1.4335 19.69 27.972 1.4206 
30 81.899 123.12 1.503375.29 107.89 1.433 19.68827.953 1.4198 
40 81.889 123.03 1.502475.279 107.8 1.432 19.68227.9 1.4176 
50 81.873 122.88 1.500975.259 107.641.4302 19.66927.8061.4317 
60 81.8 122.55 1.498275.213 107.38 1.4277 19.64827.671 1.4083 
70 58.33976.999 1.308365.08287.095 1.3382 19.61427.493 1.4017 
80 42.07355.34 1.315346.79759.362 1.274 19.46527.16 1.3953 
90 24.88834.093 1.369826.425 35.214 1.3326 17.35 23.805 1.3721 
100 19.55527.201 1.391 20.391 27.752 1.361 15.33520.948 1.366 
110 15.37 21.677 1.410415.75521.8241.3852 13.02717.8161.3676 
120 11.747 16.788 1.4291 12.084 17.015 1.4081 10.47 14.372 1.3727 
140 6~5996 9.8171 1.48756.78979.9073 1.45926.04968.5513 1.4135 
160 4.81327.3169 1.52024.88127.28541.49254.26156.17211.4483 
180 3.4643 5.3914 1.5562 3.4661 5.3035 1.5301 2.94524.398 1.4933 
200 1.72632.8058 1.6253 1.7311 2.7605 1.5946 1.414 2.2181 1.5687 
glO.mat 
o 47.34470.429 1.487644.93964.16 1.4277 14.04620.232 1.4404 
10 47.34470.429 1.487644.93964.16 1.4277 14.04620.232 1.4404 
20 47.34370.427 1.487644.93964.158 1.4277 14.04620.2311.4403 
30 47.34 70.389 1.486944.93564.125 1.427 14.04520.215 1.4393 
40 47.33270.308 1.485444.95364.04 1.4255 14.03920.168 1.4366 
50 47.31770.178 1.483244.90863.8981.422914.02820.0841.4318 
60 47.29470.002 1.480244.87963.703 1.4194 14.009 19.963 1.4251 
70 47.12769.472 1.471444.79363.3561.4144 13.983 19.813 1.417 
80 44.39363.5611.431843.61660.8341.3947 13.96619.7261.4124 
90 24.03 32.441 1.35 26.19934.359 1.3115 13.621 19.017 1.3962 
100 18.30225.252 1.3798 19.48826.1641.3426 12.729 17.617 1.384 
110 14.19 19.924 1.4041 14.808 20.35 1.3743 11.294 15.562 1.3779 
120 10.982 15.656 1.4256 11.293 15.822 1.4011 9.5185 13.133 1.3797 
140 6.14129.0926 1.48066.3683 9.2591 1.45395.7639 8.1313 1.4107 
160 4.47956.7776 1.513 4.58776.8143 1.48544.13175.9503 1.4402 
180 3.19854.9561 1.54953.22844.91811.52342.83764.2092 1.4834 
200 1.58182.5663 1.6224 1.586 2.5286 1.5943 1.3413 2.1016 1.5668 
71 
to 
g1S.mat 
o 47.34470.429 1.487644.93964.16 1.4277 14.04620.232 1.4404 
10 47.344 70.429 1.487644.93964.16 1.4277 14.04620.232 1.4404 
20 47.34370.427 1.487644.93964.158 1.4277 14.04620.231 1.4403 
30 47.34 70.389 1.486944.93564.125 1.427 14.04520.215 1.4393 
40 47.332 70.308 1.485444.953 64.04 1.4255 14.03920.168 1.4366 
50 47.31770.178 1.483244.90863.898 1.4229 14.02820.084 1.4318 
60 47.29470.002 1.480244.87963.703 1.4194 14.009 19.963 1.4251 
70 47.12769.472 1.471444.79363.3561.414413.983 19.813 1.417 
80 44.39363.5611.431843.61660.834 1.3947 13.966 19.726 1.4124 
90 24.03 32.4411.35 26.19934.3591.3115 13.62119.017 1.3962 
100 18.30225.252 1.3798 19.48826.1641.3426 12.72917.617 1.384 
110 14.19 19.924 1.404114.80820.35 1.3743 11.294 15.562 1.3779 
120 10.982 15.656 1.4256 11.293 15.822 1.4011 9.5185 13.133 1.3797 
140 6.14129.0926 1.48066.3683 9.25911.45395.76398.1313 1.4107 
160 4.47956.77761.513 4.58776.8143 1.48544.13175.9503 1.4402 
180 3.19854.9561 1.54953.22844.9181 1.52342.83764.2092 1.4834 
200 1.58182.5663 1.6224 1.586 2.5286 1.5943 1.3413 2.1016 1.5668 
g20.mat 
o 13.44220.409 1.5183 13.314 19.641 1.47525.68568.7105 1.532 
10 13.44220.409 1.5183 13.314 19.641 1.47525.68568.7105 1.532 
20 13.44220.407 1.5182 13.314 19.64 1.4751 5.68558.7101 1.532 
30 13.44 20.382 1.5166 13.312 19.618 1.4737 5.68448.6991 1.5303 
40 13.43420.328 1.5132 13.306 19.5611.4701 5.6807 8.6677 1.5258 
50 13.42420.24 1.5077 13.293 19.465 1.4643 5.6728 8.6109 1.5179 
60 13.40920.119 1.5005 13.274 19.331 1.45635.65988.5276 1.5067 
70 13.388 19.974 1.4919 13.248 19.1691.44695.64188.4228 1.4929 
80 13.375 19.892 1.4873 13.233 19.0791.44175.63068.36211.4851 
90 13.34119.7011.4767 13.195 18.873 1.43035.60268.2217 1.4675 
100 13.23 19.425 1.4682 13.121 18.667 1.42275.58558.1419 1.4577 
110 12.35117.802 1.4413 12.534 17.603 1.40445.55928.0447 1.4471 
120 9.5972 13.447 1.4011 10.236 14.056 1.37325.46237.8369 1.4347 
140 5.15157.5103 1.45795.34497.64911.43114.40676.2503 1.4184 
160 3.7617 5.605 1.49 3.8875 5.7021 1.4668 3.48094.9776 1.4299 
180 2.68064.0976 1.52862.76744.1585 1.50272.54893.7157 1.4578 
200 1.29282.0832 1.6114 1.29972.0645 1.5885 1.1637 1.8079 1.5536 
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g25.mat 
o 8.3731 13.028 1.556 8.3736 12.713 1.51823.90646.205 1.5884 
10 8.373113.028 1.556 8.3736 12.713 1.51823.90646.205 1.5884 
20 8.373 13.027 1.55588.3735 12.712 1.5181 3.9064 6.2048 1.5884 
30 8.3712 13.007 1.5537 8.3718 12.694 1.51633.90556.1957 1.5864 
40 8.3668 12.962 1.54928.3667 12.647 1.51163.9025 6.17 1.581 
50 8.3584 12.889 1.5421 8.3564 12.568 1.504 3.896 6.1232 1.5717 
60 8.3454 12.789 1.5325 8.3403 12.457 1.49363.88526.0541 1.5583 
70 8.328 12.668 1.5211 8.3191 12.322 1.48123.8701 5.9666 1.5417 
80 8.3175 12.599 1.51488.3063 12.246 1.4743 3.86065.9154 1.5322 
90 8.292 12.444 1.50088.2758 12.075 1.459 3.83685.7963 1.5107 
100 8.2759 12.357 1.4931 8.2576 11.979 1.45073.82255.7285 1.4986 
110 8.2338 12.22 1.4841 8.2226 11.853 1.4415 3.8065 5.6556 1.4858 
120 7.9381 11.645 1.467 8.0108 11.436 1.42763.78535.5725 1.4721 
140 4.80666.9265 1.441 5.0871 7.1683 1.4091 3.50645.0596 1.443 
160 3.48465.1556 1.4795 3.6167 5.2551 1.453 3.00754.328 1.4391 
180 2.4926 3.7817 1.5172 2.5757 3.847 1.4936 2.3286 3.3866 1.4543 
200 1.1956 1.9179 1.6042 1.2105 1.9137 1.581 1.1032 1.6992 1.5403 
g35.mat 
o 3.78636.2747 1.65723.83336.2411 1.6281 2.02463.4752 1.7165 
10 3.78636.2747 1.65723.83336.2411 1.6281 2.02463.4752 1.7165 
20 3.78626.2738 1.657 3.83326.2405 1.628 2.02463.475 1.7164 
30 3.785 6.2604 1.654 3.8321 6.2285 1.62542.024 3.4691 1.714 
40 3.78216.2305 1.64743.82866.19721.61872.02193.4517 1.7072 
50 3.77646.1812 1.63683.82176.1434 1.60752.01763.42 1.6951 
60 3.76756.1124 1.62243.81066.067 1.5921 2.0101 3.3726 1.6778 
70 3.75536.0276 1.6051 3.7958 5.9727 1.5735 1.99963.3114 1.656 
80 3.74785.979 1.5953 3.7867 5.9188 1.5631 1.99283.2751 1.6434 
90 3.72935.8675 1.57343.76465.7958 1.5395 1.97553.1889 1.6142 
100 3.71825.8047 1.5611 3.7517 5.7269 1.5265 1.96493.139 1.5976 
110 3.706 5.7381 1.5483 3.7375 5.6539 1.5127 1.953 3.085 1.5796 
120 3.69225.6667 1.53483.72195.5764 1.4983 1.93993.027 1.5604 
140 3.54465.3234 1.50183.59785.2729 1.4656 1.90672.8957 1.5187 
160 3.02674.4771 1.47923.14544.5536 1.4477 1.85942.7836 1.4971 
180 2.17443.2458 1.49272.27973.3362 1.4634 1.70042.5183 1.481 
200 1.0428 1.6536 1.5858 1.0724 1.6752 1.5621 0.9889 1.4999 1.5166 
73 
... 

g50.mat 
o 1.44522.6812 1.8552 1.48072.71911.83640.88457 
10 1.44522.6812 1.8553 1.48072.7192 1.83640.88457 
20 1.44522.6807 1.855 1.48062.7189 1.83630.88455 
30 1.44452.6736 1.8508 1.48 2.7124 1.83260.88423 
40 1.44292.6571 1.8415 1.4781 2.69511.82330.88312 
50 1.4397 2.6295 1.8264 1.4743 2.665 l.8077 0.88068 
60 l.43472.5903 1.8055 l.468 2.6215 1.78580.87646 
70 1.4275 2.5407 1.7798 1.4593 2.5665 l.7587 0.87027 
80 1.423 2.5117 1.765 1.45382.5343 1.74320.86617 
90 1.41152.4432 1.7309 1.44022.4588 l.7073 0.85537 
100 1.40452.40361.7114 1.43192.41541.68680.84854 
110 l.3965 2.3608 1.6905 1.4228 2.3686 1.6648 0.84077 
120 1.38772.3149 1.6681 l.4127 2.3185 1.64120.83204 
140 1.3675 2.2147 1.6195 l.3899 2.2098 1.5899 0.81186 
160 l.354 2.1574 1.5934 l.3755 2.149 1.5623 0.80044 
180 1.31652.0623 1.5665 1.34092.0576 l.5345 0.78682 
200 0.8573 1.3328 1.55460.8932 1.3644 1.52740.68338 
g65.mat 
o l.18722.2223 1.8719 l.2 2.1109 1.7591 0.71766 
10 1.18722.2223 1.87191.2 2.11091.75910.71766 
20 l.1872 2.22191.8715 l.2 2.1107 l.759 0.71765 
30 1.18672.2161 1.8674 1.19962.1067 1.75620.71748 
40 1.18552.2034 1.8586 1.19852.0964 l.7492 0.7169 
50 1.18332.1826 l.8445 l.1963 2.0787 l.7376 0.71561 
60 1.17982.1533 1.8251 l.1927 2.05291.72120.71334 
70 1.17492.1165 1.80141.18762.01981.70080.7099 
80 1.17182.0948 1.7877 1.18432.00021.689 0.70756 
90 1.16372.0435 1.756 1.1758 1.9533 1.66120.70119 
100 1.15872.0138 1.7379 1.1706 1.9259 1.64520.69705 
110 l.1531 l.9814 1.7183 l.1647 1.8959 1.62780.69225 
120 1.1468 1.9465 1.6974 l.1581 1.8633 1.609 0.68675 
140 1.1321 l.8699 1.6517 1.1429 l.7913 1.56740.67374 
160 l.1223 l.826 1.627 1.1331 1.7504 1.54490.66623 
180 1.0952 1.753 1.6006 1.1088 1.687 1.5215 0.65705 
200 0.7340 l.1562 1.57520.7614 1.1501 l.5103 0.57862 
l.7117 1.9351 
1.7117 1.9351 
1.7116 l.935 
1.7084 l.9321 
l.6988 l.9237 
1.68111.9089 
1.6541 l.8872 
1.6183 l.8595 
1.5965 1.8432 
1.5434 1.8043 
l.51171.7815 
l.4768 1.7565 
l.4387 l.7291 
1.3539 1.6676 
1.3076 1.6336 
1.2573 1.598 
1.053 l.5408 
1.2954 1.8051 
1.2954 1.8051 
1.2954 1.8051 
1.2937 1.8031 
1.2887 1.7976 
l.2793 1.7878 
l.2649 1.7732 
l.2452 1.7541 
1.233 1.7426 
l.2024 l.7148 
1.1836 1.698 
l.1626 1.6794 
1.1391 1.6587 
1.0858 1.6116 
1.0561 1.5852 
l.0233 1.5574 
0.8745 1.5115 
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g85.mat 
o 0.9129 1.6211 1.77570.9227 1.525 i.6526 0.5571 0.9362 1.6804 
10 0.9129 1.62111.77570.9227 1.525 1.65260.5571 0.9362 1.6804 
20 0.9128 1.6208 1.7755 0.9227 1.524 1.6525 0.5571 0.9361 1.6804 
30 0.9126 1.618 1.77290.9226 1.5231 1.65090.55700.9354 1.6794 
40 0.9120 1.6118 1.7671 0.9221 1.5185 1.64670.55680.9333 1.6763 
50 0.9109 1.6015 1.758 0.9211 1.5104 1.63970.55620.9293 1.6707 
60 0.9092 1.5868 1.74530.9194 1.4986 1.62980.55520.9229 1.6623 
70 0.9066 1.568 1.72940.9169 1.483 1.61720.55360.9140 1.6509 
80 0.9049 1.5566 1.7201 0.9153 1.473 1.6097 0.5525 0.9083 1.6439 
90 0.9005 1.529 1.698 0.91091.4499 1.59160.54930.8933 1.6263 
100 0.8976 1.5126 1.685 0.9081 1.4356 1.58090.5471 0.8838 1.6153 
110 0.8943 1.4943 1.6708 0.9048 1.4197 1.569 0.5446 0.8728 1.6028 
120 0.8906 1.4743 1.65540.9010 1.402 1.55590.54150.8603 1.5887 
140 0.8816 1.4294 1.62120.8921 1.3618 1.52640.5341 0.8309 1.5555 
160 0.8755 1.4029 1.60230.8862 1.3382 1.51 0.52970.8141 1.5367 
180 0.8579 1.3568 1.58150.8706 1.2994 1.49260.52420.7949 1.5165 
200 0.59530.9255 1.55460.61780.9158 1.48240.46800.6936 1.4822 
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